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This is rather as if you imagine a puddle waking up one morning and 
thinking, "This is an interesting world I find myself in — an interesting 
hole I find myself in — fits me rather neatly, doesn't it? In fact it fits me 
staggeringly well, must have been made to have me in it!" This is such a 
powerful idea that as the sun rises in the sky and the air heats up and as, 
gradually, the puddle gets smaller and smaller, frantically hanging on to 
the notion that everything's going to be alright, because this world was 
meant to have him in it, was built to have him in it; so the moment he 
disappears catches him rather by surprise. I think this may be something 
we need to be on the watch out for. 
 
Douglas Adams. The Salmon of Doubt 
	  
	Abstract 
This thesis investigates the mechanisms behind human pregnancy duration. Too short 
gestation is a direct cause of perinatal, neonatal, and infant mortality. Deviation from 
normal pregnancy length is also associated with a child's morbidity, even in the 
adulthood. The mechanisms determining pregnancy duration are not understood well 
enough to design an effective preterm birth prevention method, nor a method that 
would prevent preterm birth sequelae. The three included studies use genomic and 
epidemiological methods to contribute to our understanding of causal factors 
triggering birth. 
Study I is a hypothesis-free genome-wide search for genetic variants affecting 
gestational age at birth. The study uses genotyped mothers (n=1921) and children 
(n=1199) from a Norwegian cohort MoBa. While finding no statistically significant 
associations, the study empirically shows that the top implicated loci are enriched in 
genes biologically relevant to the field of obstetrics and gynecology, and that the 
enrichment is mainly caused by infection/inflammation-related genes. 
Study II explores whether a well-known association between maternal height and 
duration of pregnancy could be causally linked. It utilizes a novel adaptation of 
Mendelian randomization, which is based on the non-transmitted maternal haplotype 
and its polygenic risk score for human height. With the help of genomic data from 
3485 mother-child pairs from Nordic countries, the study confirms the causal 
relationship. 
Study III follows up on the findings from the Mendelian randomization study, this 
time using non-genetic epidemiological data to explain the mechanism behind the 
causal relationship. A uterine distention hypothesis is formulated and tested by 
comparing the expected and observed patterns of interaction between fetal growth 
rate, maternal height and the child's gestational age at birth. The twin (n=2846) and 
singleton (n=527 868) data is obtained from the Swedish Medical Birth Register. 
Since the observed and expected interaction patterns agree with each other, the study 
concludes that uterine distention is likely to be one of the causal mechanisms 
regulating pregnancy duration. 
 
Keywords: gestational age at birth, preterm delivery, preterm birth, genome-wide 
association study, GWAS, enrichment, Mendelian randomization, causality, uterine 
distention, interaction. 
 
 
 
 	
  
	Sammanfattning på svenska 
Denna avhandling undersöker mekanismerna bakom graviditetens längd hos 
människa. Förtidsbörd är den främsta orsaken till perinatala och neonatala 
komplikationer och dödligheten hos barn upp till 5 år. Avvikelse från normal 
graviditetslängd är också associerad med barnets sjuklighet, även upp i vuxen ålder. 
De mekanismer som bestämmer graviditetslängd hos människa förstås inte i tillräcklig 
omfattning för att man skall kunna utforma en effektiv strategi för att förebygga 
förtidsbörd eller dess följder. De tre inkluderade studierna i den här avhandlingen 
använder genomiska och epidemiologiska metoder, för att bidra till ökad förståelse av 
orsakssamband till varför förlossningen hos människa startar vid en viss tidpunkt. 
Studie I är en hypotesfri undersökning av hur olika genetiska varianter påverkar 
graviditetslängden vid förlossning. Studien använder sig av genotypade mammor 
(n=1921) och barn (n=1199) från en norsk kohort (Den norska mor-barn studien, 
MoBa). Trots att inga statistiskt signifikanta associationer hittades, visar studien ändå 
att det är främst loci i gener som är biologiskt relevanta inom området för obstetrik 
och gynekologi, och att de är huvudsakligen anhopade i infektionsrelaterade gener. 
Studie II undersöker huruvida en välkänd koppling mellan mammans längd och 
graviditetens varaktighet kan ha ett orsakssamband och inte bara en epidemiologisk 
association. Den utnyttjar en ny variant av så kallad Mendelsk randomisering, som är 
baserad på den icke-transmitterade maternella haplotypen och dess beräknade 
genetiska risk för mammans längd. Med hjälp av genomisk data från 3485 mor-barn 
par från nordiska länder bekräftar studien orsakssambandet. 
Studie III följer upp resultaten från den Mendelska randomiseringsstudien. Denna 
gång med icke-genetiska epidemiologiska data för att förklara den bakomliggande 
mekanismen till orsakssambandet. En hypotes testas om att det är livmoderns 
utspänning som är en av mekanismerna. Genom att jämföra de förväntade och 
observerade mönstren av interaktion mellan fetal tillväxt, mammans längd och 
graviditetens längd vid förlossningen finner man ett sådant samband. Information om 
enkelbörder (n=527 868) och tvillinggraviditeter (n=2846) erhölls från det svenska 
medicinska födelseregistret. Eftersom de observerade och förväntade 
interaktionsmönstren överensstämmer med varandra, drar studien slutsatsen att 
livmoders utspänning sannolikt kommer att vara en av de kausala mekanismerna som 
reglerar graviditetens varaktighet hos människa. 
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1. Abbreviations 
DNBC Danish National Birth Cohort 
FIN  Finnish cohort 
GA  gestational age at birth 
GWAS genome-wide association study 
IVF  in vitro fertilization 
LGA  large for gestational age 
LMP  last menstrual period (also a method for GA dating) 
MAF  minor-allele frequency 
MoBa  Norwegian Mother and Child Cohort 
MR  Mendelian randomization 
PROM prelabor rupture of fetal membranes 
PTD  preterm delivery (also, preterm birth) 
QC  genotyping-data quality control 
SGA  small for gestational age 
SNP  single-nucleotide polymorphism 
UL  ultrasound method for GA dating (from Swedish "ultraljud") 	  
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2. To the Reader 
Biomedical science is volatile. Its methods evolve ever so quickly. In ten years from 
now, it might be difficult to imagine what it was like to do science in 2018. The 
professor, who introduced me to the field of genomics back in 2010, once told a joke 
about how all experiments that took her an entire PhD to perform, today could be 
repeated overnight. I feel that a reflection on a current context could make this thesis 
more inviting. So, to those who read this in the future, I would like to describe the 
today of my present.  
The "dark ages of DNA" are now over, symbolically marked by a recent death of its 
last doge - Luigi Luca Cavalli-Sforza*. His was an epoch of blood-group population 
genetics, single-marker association studies, and Mendelian phenotypes. Now we find 
ourselves in the Renaissance of the Genetic Era1. In it, reading a full human genome 
using sequencing technology is fast and affordable, although it still costs around 70 
hourly wages†. Full-genome association studies are published at a rate of 4000 per 
year, but the largest genotyped cohorts still have fewer than 1 million humans. Today, 
an typical genomics researcher has an access to computational power equivalent to 
200 billions instructions per second; quantum computing is in its fetal stage and not 
practical yet. Just recently, as part of ancient-DNA revolution we learned about 
geographical as well as intimate adventures of our ancient ancestors and their cousins 
Neanderthals and Denisovans - only by sequencing their 50,000-year-old bones1. 
Genome editing, too, has made a huge leap with CRISPR/Cas9 technology - early 
clinical trials on humans are already taking place. Today we are wondering what will 
come first - a widely spread therapeutic gene editing or a wild spread of (currently) 
extinct woolly mammoth2. Last year, de novo genome synthesis and assembly has also 
reached a milestone of 1MB3. An average person today is already worried about the 
climate change, some have concerns about the development of artificial intelligence, 
but most are still oblivious of potential dangers of engineered gene drive systems4 or 
terrorists using synthetic pathogens5. The cost of developing a prescription drug that 
gains market approval is equivalent to a budget of 42 flights to the geosynchronous 
transfer orbit with 8 tons of payload each‡.  
As a contrast, the field of obstetrics has been stagnant for at least a decade. The 
non-invasive prenatal tests using cell-free DNA to screen for trisomies are now 
commercially available but have not replaced amniocentesis. In some regions, 
magnesium neuroprotection and progesterone6 treatments have been introduced into 
clinical routine, as well as fibronectin test7. Nonetheless, one in ten babies on the 
planet are still born too early. For those born very early, the mortality rate gap 
between high- and low-income countries is currently 10% vs 90%. 																																																								
* Dr. Cavalli-Sforza [25 January 1922 - 31 August 2018] died two weeks after I decided to honour 
him in a metaphor.  
† with current median income in Sweden. 
‡ SpaceX's Falcon-9 launch prices for 2018. 
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3. The Phenotype 
3.1. Gestational Age 
3.1.1. Meaning, synonyms and units 
During conversations with people outside the field of medicine, I have noticed that the 
most convenient way to describe the object of my research is "the time a baby spends 
inside the mother's womb". Despite being perfectly inaccurate, this definition is where 
we should start the journey. There are other technical names to call it: "a child's 
gestational age at birth", "gestational duration", "gestational length", "pregnancy 
duration", "pregnancy length", and "timing of birth". As there is no strict consensus on 
the preferred term, I will use them interchangeably, with a slight bias towards my 
favourite - "gestational age" (GA, with an implicit note that this age is evaluated at 
birth). 
Gestational age can be evaluated in time units - months, weeks or days. That 
depends on a context. While it is convenient to refer to "months" in casual 
conversations, obstetricians usually refer to weeks and academic scholars use the 
smallest unit of measurement practically available - days. As this might relay an 
impression of perfect precision, I would like to stress that this number is rarely 
correct. In fact, it is almost never correct. The first day of an organism’s existence is 
the day a sperm fertilizes an egg. In most practical settings involving humans, the 
fertilization time is not known*, thus the time difference between conception and birth 
can only be guessed, guesstimated, estimated - but not measured. 
3.1.2. Methods of estimation 
Two time points are required to determine GA. The date of birth is always known to 
the accuracy of minutes. Determining the date of fertilization, on the other hand, is 
tricky. All currently applied GA evaluation methods try to estimate the day of 
conception using extraneous signs, as fertilization event itself is ethically undetectable 
in natural human pregnancies. The estimations are based on various assumptions that 
are not guaranteed to hold.  
The last menstrual period (LMP) method assumes that ovulation occurs on the 14th 
day (or mid-cycle) after the LMP. This is rarely the case due to personal variation and 
population variation in menstrual cycle length (short, long, irregular). Another 
assumption is that the fertilization day is on the same day as ovulation (although it is 
pretty accurate). This method also relies heavily on a recall accuracy of the self-
reported LMP date. 
																																																								
* An exception could be IVF pregnancies. 
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The ultrasonographic (UL) measurement method uses fetal growth curves 
previously derived by a combination of UL and LMP methods in women with very 
regular menstrual cycles. UL method assumes that, while in early developmental 
stages (e.g., first trimester), all fetuses of the same true age have no variation in fetal 
size (e.g., crown-rump length, biparietal diameter). It also relies on the reference 
population, equipment accuracy and personnel skills (intra-operator and inter-operator 
variability). 
Other methods rely on detection of the ovulation event (by monitoring basal body 
temperature or changes in the hormone levels) or the implantation event (monitoring 
human chorionic gonadotropin levels). These methods also assume that fertilization 
date can be reliably inferred from ovulation or implantation dates8. But most 
importantly, they require a meticulous personal longitudinal record keeping, thus are 
not a part of a standard medical practice. 
A very important caveat remains to be stated. Even if the true date of fertilization is 
known, GA is not recorded as the true time difference between fertilization and birth 
event (as would be more than reasonable to do). A conventional "correction" of 14 
days would be added to create a compatibility with historical records that only 
registered uncorrected LMP date as the starting point of pregnancy. 
3.1.3. Which method of estimation is the best? 
 
When compared among each other, the four methods of estimating gestational length 
show the following order of accuracy: ovulation > implantation > UL > LMP9. 
However, due to practical reasons, only LMP and UL can be considered in standard 
medical practice, as the other two methods would require daily monitoring and would 
dependent on the skills* and determination of the woman herself. 
UL is currently the most common GA dating method in Sweden; over the last four 
decades it has gradually pushed the LMP method (Figure 1) to a relative obscurity. In 
the three studies covered by this thesis, the GA data was mostly or exclusively 
generated by UL method. The second-trimester UL scan measures fetal head 
circumference via the biparietal diameter and the occipital-frontal diameter. This 
method is less accurate than the first-trimester UL measurement of the crown-rump 
length. 
When compared to the true known GA in IVF pregnancies, the UL dating was 
found to differ by +/- 8 days (range; n=1268)10. The data available to us from Studies 
I and II (MoBa) show similar inaccuracy: 95% of the differences between the true GA 
in IVF pregnancies and UL method were between -7 and +6 days (Figure 2). 
 
 
																																																								
* The cost-effective method involves meticulously registering menstrual cycles, sexual intercourses, 
and regular monitoring of basal body temperature and consistency of cervical mucus. 
	 5 
 
Figure 1. The percentage of births in Sweden dated using purely ultrasonography increased 
over time due to a combination of desirable features of this method: accuracy and practicality. 
Currently, ultrasonography is by far the most common method used to estimate gestational age 
in the developed world. In Sweden, the UL-based dating was introduced in 1982. In 1990, more 
than 50% pregnancies were dated using this method and the trend has increased ever since. 
 
Figure 2. Comparison of known gestational age and UL-estimated gestational age from IVF-
conceived pregnancies. Orange lines indicate the range of differences that contains 95% of all 
observations. Data from the Norwegian Mother and Child cohort, N=2169. As expected, IVF 
GA was on average 16 days shorter than UL GA, thus differences were centred to zero.  
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3.1.4. When do women deliver? 
In Sweden, 50% of all pregnant women give birth in a two-week window ranging 
from 273 to 286 days (39 to 41 weeks) of gestation, the mean GA is 278 days and the 
median is 280 days (Figure 3). The distribution of GA is left-skewed, which means 
that there are more early births than there are late births. Both extremes of gestational 
age (preterm and post-term delivery) increase the risks for the mother’s and baby’s 
health and life. 
 
 
Figure 3. Distribution of child's gestational age at birth. Data from the Swedish Medical Birth 
Register (2010-2013). Spontaneous and medically induced deliveries, only one observation per 
pregnancy (e.g., only one of two twins were counted). Gestational age was evaluated using UL 
method. N=293912. 
3.1.5. Why do we care about this number? 
In fetal development, maturation monotonically increases with gestational age. 
Preterm born infants are poorly adapted to the extra-uterine life. The earlier the birth - 
the lower the probability of survival11. Extremely preterm babies are born with 
severely underdeveloped brains, digestive systems, and lungs. Moreover, somewhere 
in the 22nd week of gestation there is the so-called "limit of viability", which refers to 
the minimum gestational age at which a baby currently can survive outside the womb.  
It is tempting to rush to the conclusion that the best time to be born is as late as 
possible. However, a post-term birth also bears death-related risks, not only to a child, 
but to a mother too - via complicated birth.  
The major part of obstetrics is about defining the best time of delivery for both 
mother and child, aiming to either prolong gestation or induce delivery for some 
medical reason. 
220 230 240 250 260 270 280 290 300
Gestational age at birth (days)
De
ns
ity
 (%
)
0
1
2
3
4
5
32 33 34 35 36 37 38 39 40 41 42 43
completed weeks:
	 7 
3.2. Preterm Birth 
3.2.1. Definition 
Preterm birth, or preterm delivery (PTD), is historically defined as a childbirth 
occurring at less than 37 completed weeks (259 days) of gestation. There are other 
more nuanced classifications of gestational duration (Table 1); however, they will not 
be used in this thesis.  
 
 Table 1. Extended classification of gestational age. 
 Gestational age at birth 
Categories Completed weeks Gestational day 
Post-term birth 420/7  - 294 - 
Late term 410/7 - 416/7 287 - 293 
Full term 390/7 - 406/7 273 - 286 
Early term 370/7 - 386/7 259 - 272 
Moderate or late preterm birth 320/7 - 366/7 224 - 258 
Very preterm birth 280/7 - 316/7 196 - 223 
Extremely preterm birth - 276/7 - 195 
 Based on12,13. The nomenclature of GA is typically discussed in terms of the number of  
 "completed weeks", but in statistical analyses we have uses gestational days.  
The current PTD definition only provides a standardized language but lacks 
medical or biological meaning. The chosen threshold for gestational age is arbitrary, 
as the earlier the separation line, the grimmer the birth outcomes. The major transition 
in terms of needing special care occurs between 34 and 37 weeks14. Some also suggest 
that the current threshold does not serve a useful purpose, because it does not coincide 
with functional maturity, thus should be shifted to 39 weeks15.  
In general, "preterm" should be distinguished from "premature", which describes a 
lack of completed fetal development16. To exemplify the importance of this 
distinction: preterm born Black and Asian infants (compared to white European 
infants) have higher fetal maturity, even though PTD rates in these ethnicities are 
higher17. Unfortunately, approximating maturity by gestational days is much more 
scalable (simple, cheap, familiar, universal) than quantifying the maturity.  
The rate of PTD is estimated as all live births before 37 completed weeks (whether 
singleton, twin, or higher order multiples) divided by all live births in the population. 
THE	PHENOTYPE	
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The best estimate of global PTD rate is 11.1%, although country-wise rates range 
from 5% to 18%18. 
The major classification of PTD includes two groups: (1) spontaneous preterm 
delivery and (2) provider-initiated preterm delivery (defined as induction of labor or 
elective Caesarean section before 37 completed weeks of gestation for maternal or 
fetal indications or other non-medical reasons). The second group used to be called  
“iatrogenic”. Since provider-initiated preterm births are regionally and temporally 
dependent on public policies and developmental level of medical care, we often 
exclude these types of PTD from analyses. In all three studies covered by this thesis 
similar action was taken. 
It is useful to mention the subclassification for the first group based on how the 
delivery starts: (1a) spontaneous labor with intact membranes, (1b) preterm prelabor 
rupture of the membranes. 
3.2.2. Consequences 
Mortality 
Preterm birth is the leading cause of child deaths worldwide: according to the latest 
global estimate, 15.4% of all the deaths before age 5 were a direct cause of preterm 
birth19. From the year 2000 to 2013, global child mortality dropped; however, the rate 
of reduction attributable to PTD was one of the smallest out of 17 death causes19.  
Most of these lives are lost during the challenging neonatal period (28 first days of 
extrauterine life). The common reasons of neonatal death in preterm-born babies are 
respiratory distress syndrome (breathing difficulty caused by deficiency of surfactant, 
also known as hyaline membrane disease), bronchopulmonary dysplasia (due to 
prolonged mechanical ventilation and supplemental oxygen), necrotising enterocolitis 
(seen almost exclusively in preterm infants), intracranial non-traumatic hemorrhage 
(with no history of birth or post delivery trauma)20. In Level 1 income countries21, the 
list expands to neonatal infections, hypothermia, and malnutrition.  
Over the last five decades, due to advancements in medical care, in high-income 
countries neonatal mortality rate has significantly dropped in every strata of 
gestational age22. But this has also widened the survival gap between high- and low-
income countries, which is currently 90% vs 10%23. 
During the neonatal period, preterm-born babies can experience retinopathy of 
prematurity caused by oxygen toxicity (supplementary oxygen received at neonatal 
intensive care unit), which leads to hypoxia and abnormal blood vessel development 
in the retina. Even though not deadly, this condition will lead to blindness or severe 
myopia, thus contributing to morbidity later in life. 
Premature infants have a very high readmission rate in the three months after 
discharge24. Readmission is often related to jaundice25, also to respiratory infection26. 
 
 
 
	 9 
Morbidity 
Preterm-born children often have a lifetime of significant disability. On a global level, 
of those who survive beyond the first month, 2.7% are estimated to have moderate or 
severe neurodevelopmental impairment, and additional 4.4% to have mild 
neurodevelopmental impairment20. An estimated 31% of preterm-born children have 
at least one of the problems: cognition impairments, general developmental delay or 
learning difficulties; cerebral palsy; impaired vision or blindness, gross motor and 
coordination impairments; deafness or hearing loss; epilepsy; behavioural problems 
(sorted by decreasing frequency)27. Cognitive and neurologic impairments were still 
evident at starting school age28.  
In Sweden, 36.1% of extremely preterm children had no disability, 30.4% had mild 
disability, 20.2% had moderate disability, and 13.4% had severe disability (evaluated 
at 6.5 years of age; includes cerebral palsy, vision, hearing, and cognitive disability)29. 
At age 11, preterm-born kids significantly more often had functional limitations, 
compensatory dependency needs, and services above those routinely required by 
children30. A lower mean intelligence quotient31 and a decline in mean intelligence 
quotient over time in childhood is documented32. In the adulthood, of those who are 
born preterm, significantly fewer complete the high school or university, more of 
them receive Social Security benefits and have medical disabilities severely affecting 
working capacity, less have a high job-related income, less get married or have a 
partner and less become biological parents22. 
3.2.3. Obstetric care 
First of all, it is worth mentioning the existing preventive measures. These include 
generic common-sense recommendations to women, such as leading a healthy life 
style, good nutrition, physical activity, vitamins and supplements, emotional health33. 
In practice, it would be naive to expect a high effectiveness of such guidelines. They 
are hard to adhere to. But if we were to imagine a "platonic pregnancy cohort" in 
which every woman follows the World Health Organisation recommendations33, we 
would be likely to find much lower PTD rates than in the real world34. 
Besides prevention, there is prediction. It could be useful to have a tool that 
identifies women at risk. This would give doctors more time to act, would assure that 
women are monitored and do not deliver at home by accident. Currently, the best 
predictors of preterm birth are personal history of PTD, cervical length35, and 
fibronectin36. The composite predictive model is far from perfect37 and does not help 
to prevent PTD nor improve perinatal outcome7.  
Lastly, there is treatment. Or rather, there is no good treatment. In preterm birth, 
two complementary directions could be mentioned: (1) reduction of adverse 
consequences to the fetus, and (2) prolongation of pregnancy. In (1), there are 
corticosteroids that accelerate maturation of fetal lungs (essential for fetal viability) 
and brain, also neuroprotective effects of magnesium sulphate (decreased incidence 
and severity of cerebral palsy, neonatal intraventricular hemorrhage and 
periventricular leukomalacia)38. In (2), there are tocolytics (labor suppressants) that 
postpone delivery to some extent, allowing the corticosteroid treatment.  
THE	PHENOTYPE	
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The effectiveness of tocolysis is arguable39,40. Antibiotics may too prolong the 
pregnancy for a couple of days but their use is associated with higher rate of neonatal 
necrotizing enterocolitis41, almost double risk of cerebral palsy42, and the benefit of 
antibiotics used prophylactically in a general population or therapeutically in preterm 
labor with intact membranes is neither proven nor recommended42.  
It is generally considered that progesterone administration reduces the rate of 
preterm birth and improves neonatal outcome. However, progesterone has only been 
shown to improve child outcome in risk pregnancies: women with short cervical 
length (less than 2% of pregnant women), or for women with previous PTD (less than 
10% of pregnant women). The remaining majority is not recommended progesterone 
and thus remains at risk43. Latest studies show that progesterone is generally 
ineffective6. 
To summarize, modern obstetrics does not have a solution on how to regulate 
pregnancy duration. At least, not to the extent which would allow the prevention of 
preterm birth. Due to advancements in obstetrics and neonatology, more children that 
would otherwise be born dead due to extreme prematurity are now born alive  
(Figure 4), although only a small fraction of survivors are expected to live a regularly 
healthy life. One positive note: human clinical trials might soon be approved to test 
the extra-uterine system recreating the intrauterine environment (artificial womb, or 
"baby bag"). This system was recently shown to improve the condition of preterm-
born lambs44,45. 
 
Figure 4. The decreasing trend of gestational age of live-born children in the 0.05th percentile 
of gestational age. Swedish Medical Birth Register (1982-2013), spontaneous and medically 
induced pregnancies with at least one live-born child and UL-based GA dating. The numbers on 
the right indicate gestational age in completed weeks. Dark dots are the 0.05th percentile of 
gestational age, and vertical lines are the 95% confidence intervals estimated using bootstrap 
method. For comparison, the thick curve in the background represents the mean gestational age 
of the population lowered by 101.6 days to match the mean of 0.05th percentile data. 
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3.3. Post-term birth 
Post-term delivery is defined as delivery after 416/7 completed weeks of gestation (294 
days and further). During the post-term period the fetus is at a higher risk for 
intrauterine death, hypoxia and subsequent meconium aspiration syndrome. With 
larger fetus, delivery might be complicated by obstructive labour, shoulder dystocia, 
plexus injuries in the baby and pelvic floor injuries in the mother. The post-term 
delivery is arguably a lesser problem than the preterm birth, as it is easier to induce 
delivery than to make gestation last longer.  
3.4. Evolutionary context 
Allometric scaling studies suggest that human gestation is shorter relative to other 
primates and that 18–21 months would be required for humans to be born at 
neurological and cognitive developmental stage equivalent to that achieved by a 
chimpanzee neonate46. This is thought to be caused by two phenotypic shifts, both 
favoured by natural selection: a shift from tree-climbing to bipedal locomotion, and an 
increase in the brain size and cranial volume. Considered separately, both shifts are 
advantageous; however, acting together they impose a new threat to the evolutionary 
fitness, because there is a physical limit to which the outlet size of maternal pelvic 
bones and fetal head size can vary without causing complicated childbirth. The 
“Obstetric Dilemma” hypothesis suggests that mutations shortening the time of 
gestation were favoured by the natural selection in order to avoid physical constraints 
during childbirth47. As a consequence, human neonates are born in a completely 
parent-dependent state (altriciality), the birth involves complicated head/shoulder 
rotations and unique occipitoanterior birth position, which demands assistance during 
a delivery. It might be that selective pressure towards shorter pregnancy did not push 
all involved mutations to fixation. In other words, some DNA positions that have an 
effect on pregnancy length might still contain variation in the human population: 
some individuals having the ancestral "long gestation" alleles and others having new 
"short gestation" alleles. If that is the case, we should be able to identify these genetic 
variants using genotype-phenotype association analysis (Study I). 
There are also other evolutionary forces at play. Long after the ancestral branches 
of humans and other primates have split, stabilizing natural selection must still be 
active. In prehistoric "natural" conditions, mothers delivering at far tails of gestational 
age distribution would have lower evolutionary fitness: without medical assistance, 
preterm-born children would rarely survive; post-term birth would be a serious 
mortality risk to the mother and (because of altriciality) to the newborn. Mutations 
and common genetic variants that determine extreme gestational age must have been 
selected against. Stabilizing natural selection must be favoring alleles that increase the 
likelihood of delivery at gestational age, which we with hindsight call "term". In 
modern times, due to obstetrics and neonatology, stabilizing natural selection has very 
limited power to swipe out the risk alleles. With every generation, the number of old 
and new (de novo) mutations accumulates and the population becomes more 
genetically susceptible to preterm and post-term delivery. 

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3.5. Environmental factors 
 
Even though human gestational length is still an unsolved mystery48, over the years 
numerous observations have been made about conditions and circumstances, under 
which pregnancy duration tends to be longer or shorter than normal. I will first 
describe the group of factors that could be called environmental and in the next 
subchapter I will expand on the genetic ones.  
Figure 5. Preterm delivery rates in Västra Götaland County. Only 1998-2013 births of Sweden-
born mothers with Swedish nationality were used. Gestational age was evaluated only using UL 
method. N=190892, ANOVA p<2.2e-16. Results from an on-going study. The area with the 
highest PTD rate was Gullspång (39/450 = 8.6%), and the area with the lowest rate was 
Bollebygd (45/1078 = 4.2%). 
A good example illustrating the existence of non-genetic component contributing to 
the variation in gestational age is a regional map. In Figure 5 (as well as our 
published work49) the map is colored by preterm birth incidence rate. Since only the 
pregnancies of Sweden-born Swedish nationals were used, the population is 
homogeneous and depleted from genetic factors that tend to segregate geographically 
(e.g., race). While genetic profile could be assumed uniform, each community has a 
specific environmental profile: some areas are next to the ocean, many are serviced by 
different water-cleaning stations, each has a different level of air pollution, micro-
climate etc. Since the number of environmental differences is immense and genetic 
homogeneity is strong, the significant differences in PTD rates should in large part be 
explained by variation in the environmental exposures between these geographical 
areas. In other words, some factors are environmental.  
There is a number of known environmental factors associated with shorter 
gestational age: physical traumas50, physical exertion51-53, malnutrition54, 
infection55,56, mental stress57, smoking58, also their proxy - low economical status and 
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low education59,60. Multiple pregnancy, IVF61, adolescent pregnancy or advanced 
parental age62, short inter-pregnancy interval63 - all shorten child's gestational age at 
birth and could be considered as environmental factors.  
When compared to the population average, mothers who use supplements (e.g., 
folate64) and eat healthy will deliver slightly later. 
Importantly, for many of the aforementioned risks, the cause-and-effect relationship 
(causality) has only been suggested and not proven. A thorough causal inference is a 
very tricky task when there is no ethical possibility to conduct a randomized 
controlled trial (i.e., an experiment). Studies II and III in this thesis are dedicated to 
the causality question. 
As a side note, many of the factors listed above could also be classified as genetic 
factors. For example, one must recognize that tobacco and alcohol consumption are 
dependent on genetics65,66, educational attainment is also partly a genetic trait67, as 
well as infection (due to genetic susceptibility68) and maternal stress (via genetic 
propensity for anxiety69). 
3.6. Genetic factors 
Gestational age does have a familial (genetic) nature. A palette of creative methods* 
has been used to demonstrate this.  
The first observation is that the gestational age in maternal relatives is strongly 
correlated: pregnancies of the same mother70, pregnancies of a mother and her 
daughter70, pregnancies of monozygotic twin-sisters71, pregnancies of dizygotic twin-
sisters71, pregnancies of full-sisters70, pregnancies of maternal half-sisters70. Such 
phenotypic correlation between related individuals, especially if they do not share a 
common environment, is an indication that genes are involved (Figure 6).  
 
Figure 6. Evidence for heritability in gestational age. Three equally-sized groups with 15788 pairs of 
maternal cousins. The group assignment is based on gestational age of the first cousin in a pair. The 
three overlaid density plots represent gestational age distribution of the second cousins, with original 
grouping preserved. Grey dots denote pregnancies. Data from the Swedish Medical Birth Register. 

* These methods do not rely on genetic data, only on the pedigree information and the phenotype. 
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To be clear, genes are always involved in everything (after all, all our bodies are 
built using genetic information), but what we implicitly mean by "genes are involved" 
is actually "the variation in genetic information can partially explain variation in the 
phenotype".  
The second observation is that maternal and paternal genetic contributions to 
heritability of gestational age differ. Maternal genetic effects are much stronger than 
paternal70, maybe not surprisingly, as the mother's genome can affect the pregnancy 
via her uterine environment, thus her genotype has more "expressive freedom" to 
impact the pregnancy duration as compared to the father. Since one half of the fetal 
genome is inherited from the father, the paternal genome can have an effect on 
pregnancy duration via the fetus. The paternal genetic effect is very small72,73. An 
indirect indication that fetal genes influence pregnancy length is that boys are born 
preterm more often than girls20. 
Thirdly, it must be mentioned that gestational age is not a Mendelian trait. No 
known Mendelian disorder manifests an abnormal gestational length as its primary 
clinical feature74. In other words, these phenotypes do not have a clear inheritance 
pattern. However, a very small fraction of PTD-affected families exhibit explicit 
evidence of phenotype aggregation among relatives (Figure 7, also75,76). These 
families are rare exceptions, implying a presence of low-frequency mutations with 
large effects, which are able to impair a normal progress of gestation. Despite the 
large penetrance, such rare genetic abnormalities do not explain any significant 
fraction of variance in gestational age in the population. 
Gestational age, differently than Mendelian traits, falls into a category of "complex 
traits". This means that there are many genetic variants with small effects, rather than 
one single mutation with a very strong effect. Depending on the population, the 
heritability of gestational age is approximately 30%71.  
Figure 7. Examples of rare Mendelian-like patterns of PTD familial aggregation in the Swedish 
Medical Birth Register. Individuals born preterm are highlighted in colour. Question marks 
denote missing phenotypic data. In order to protect the identity of these families, the pedigrees 
have been slightly modified without changing the general message.  
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4. Essay on Genetics 
The field of genetics is broad and fascinating. Even a thick textbook might do little 
justice to it. This chapter presents merely a couple of basic concepts and ideas that 
might be helpful to the reader without a background in genetics. To anyone outside 
this field, I would recommend exploring it deeper. The basic principle behind the 
Darwin's Theory of Evolution, when honestly and fully understood, stuns the subject 
with profound realisations about the meaning of life. I would argue that genetics can 
well compete with astronomy in its potency to change a person's life by providing a 
grander perspective.  
4.1. Human genome 
The human genome is a recipe for making humans. While being a poor technical 
definition, this gives an opportunity to introduce and address a rather common 
misconception that genomes define who we are. There is a subtle but important 
distinction between a “blueprint” and a “recipe”. The former implies a fully 
deterministic, factory-like process with a guaranteed outcome and very little variation. 
This is not what genomes are. The ”recipe”, however, is a guideline. Its success is 
much dependent on, to continue the metaphor, the interpretation of “pinch of salt” or 
“simmer until the desired consistency”. There are no blueprints in nature, but there are 
recipes. 
A human genome is also a recipe for disaster when trying to define it or explain it 
without the help of a drawing board or fancy Youtube videos. A strong warning is 
warranted: there are fascinating exceptions to almost every following statement. 
A genome is a biological storage medium for information. It is encrypted in a code 
that uses an alphabet of four letters. These letters symbolize four nucleotides - 
monomeric chemical fragments that form a long polymeric DNA molecule. At 1% of 
the genome where the genes are, DNA code is decrypted into protein-building 
instructions with a 20-letter alphabet, where each letter represents a distinct amino 
acid type. The other parts of the genome are more mysterious. In general, every cell of 
an individual has exactly the same copy of the genome. To fully describe a person’s 
genome means to name approximately 3.2 billion letters residing in one cell, and then 
to name 3.2 billion more, because human genome consists of two halves. 
One half of a person's genome is inherited from his mother while the other half - 
from his father. Each half could be called a "haploid" genome. Both halves are 
identical in their architecture, but not identical in their contents. Let us clarify this 
important idea. An analogy could be two identical houses, each with the same number 
of rooms and identical floor plan; however, furbished differently - in Modernistic and 
Victorian styles. Importantly, there is a direct functional correspondence between any 
location in house 1 and house 2, e.g., the lowest compartment always has the function 
of a basement. Similarly, any location on paternally inherited genome contains the 
same type of information as maternally inherited genome in the same location; 
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however, the flavours can differ. For example, the fragment affecting the eye colour 
will be exactly at the same location in both halves of the genome, despite encoding 
different colours. This perfect correspondence allows nature to swap fragments 
between maternal and paternal halves during the process called meiosis, thus creating 
new genomes. 
To avoid a common misunderstanding: the existence of maternal and paternal 
halves of person's genome should not be confused with the concept of "double helix". 
Each half, being a string of ‘letters’, has an identical twin, chemically attached to it, 
side by side. It is identical in a sense that it contains exactly the same information, 
only the information is written in an inverse alphabet: each A is swapped for T, each 
C is swapped for G, and vice versa. For the purposes of this thesis, we will ignore the 
twin strands and only refer to two halves of person's genome as maternal and paternal. 
The next level of complexity is chromosomes. Maternal and paternal halves of the 
genome are physically split into 23 chunks which we now can visualize as 
uninterrupted strings of letters. The chunks are of various sizes, but, as mentioned 
earlier, in terms of size and structure they are exactly the same in the maternal and 
paternal halves. One exception is the 23rd chromosome. It comes in two different 
architectures, i.e., contains different genes and, consequently, have different 
functions. One version of 23rd chromosome is called X. A person carrying two copies 
of X has a female sex. Another version of 23rd chromosome is called Y. It is much 
smaller than the X chromosome. An embryo carrying Y without X would not survive 
due to incomplete genomic recipe. The male sex humans carry one copy of X and one 
of Y.  
So far, we have ignored a small fraction of the genome located in maternally 
inherited organelles called mitochondria, and we will continue to ignore it since this 
does not directly relate to this thesis. 
4.2. Genomic variation 
Many physiological features in which we differ are due to differences in our genomes. 
Even though the human genome is large, at most of its positions we do not differ 
among each other at all. For a genetic epidemiologist, the only interesting parts of the 
genome are those where there is variation between individuals. 
Some rare forms of variation are fragment insertions, deletions, rearrangements, 
and even chromosomal duplications or omissions. But mostly, genetic differences 
between us are defined by single-position mutations, where some genomes have one 
particular letter, and some - another.  
It is common to consider mutations as being something bad. That is far from the 
truth. The core driver of evolution is the constant supply of new random mistakes in 
the genome that get judged in the fitness competition. The bad ones do not survive. 
The beneficial or neutral ones might get passed to the next generation. 
In fact, it is much better to think about mutations as "old" and "new"77. The old 
ones have spent a lot of time in human population without being eliminated by natural 
selection. Maybe because they were beneficial. Or perhaps because they had no 
detrimental effect on the reproductive fitness, and it was purely by chance, due to 
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genetic drift, that they became common. The new mutations are more likely to do 
harm. Those, which do, are likely to be rare. In all other species, any harmful 
mutation is already on its way to extinction. A caveat must be mentioned here: with a 
help of modern medicine we have placed ourselves in a position where natural 
selection can no longer see us as the players of survival game. Thus, it is less able to 
regulate the frequencies of genetic variants based on their effect on our health.  
An accidental mistake in copying the genome that turns out to be a beneficial 
mutation will likely come to a fixation. In other words, in many generations it will 
fully replace the ancestral version of itself. If there are no archaic version copies left, 
then there is no variation and we can no longer call it a mutation or a genetic variant. 
Only if fixation is not reached yet and two or more versions at the same genomic 
position are floating in the gene pool, we can call it a genetic variant or a mutation. 
Let us narrow down the genome even further, to only those variants that are 
discussed in this thesis. Firstly, we will exclude all rare mutations: if only 1 person in 
1000 has a particular mutated genomic site, then our analyses will be statistically 
underpowered. The remaining part is called single-nucleotide polymorphisms (SNPs). 
We will also ignore those SNPs that have three or four possible letters, the so-called 
multiallelic mutations, which are rarely used due to analytic complexity. We are left 
with millions of biallelic genetic markers - those that have only two alleles. One allele 
is ancestral and one is relatively new. 
At a SNP with two possible alleles, a person can have three genotypes. Let us see 
why. There are two halves of the genome. At each half, there can be only one of the 
two alleles, e.g., C or A. If a mother and a father did not choose each other because of 
their preference for a certain allele, both halves are independent. Thus, there are four 
possible combinations of alleles at this SNP per full (diploid) human genome: AA, 
AC, CA, CC; where the left-side letter indicates maternal origin, while the right-side 
letter - paternal. In genetic epidemiology we rarely care whether person’s genotype is 
AC or CA*. If allele A is harmful, then both AC and CA individuals should have the 
same risk for a disease. Moreover, the current bead-chip genotyping technology is 
unable to differentiate between the two heterozygotes. Thus, AC and CA being 
“identical”, we are left with three genotypes per one biallelic SNP. The matter could 
be much more complicated in other species (e.g., a triallelic SNP in a tetraploid 
organism would have 15 possible genotypes). 
In general, when we talk about a SNP being associated with a phenotype or a risk 
for a certain disease, we simply mean that across a population, individuals in the three 
genotypic groups at that particular genomic site have different phenotypic means or 
different disease prevalence. 
 
 
 
																																																								
* The distinction between parental origin of alleles will be of paramount importance in Study II of this 
thesis. 
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4.3. Genes in action 
A true causal SNP can exert its effect on a phenotype in various ways. It is 
convenient to classify these modes of action into three categories: additive, dominant 
and recessive effects. Assume that in a biallelic SNP with alleles T and G, the G allele 
is less common in the gene pool, thus we call it the minor allele. We often refer to the 
minor allele when talking about the three modes of action. 
An additive genetic effect is when the effect size is linearly dependent on the 
dosage of the minor allele (how many copies of the minor allele are there: 0, 1, or 2). 
An example of an additive genetic effect could be when the ranking of the three 
genotypic groups based on their risk for a disease is: TT < TG < GG (Figure 8).  
A recessive effect is when only individuals with two copies of the minor allele tend 
to get sick (or have a higher phenotypic mean). Thus, there would be no statistical 
difference between individuals in genotypic groups TT and TG, and only individuals 
in the GG genotypic group would have a differing phenotype: TT = TG < GG. 
Similarly, a dominant effect is when there is no difference in how many copies of 
the minor allele individual has, the only important thing is that there is at least one 
copy: TT < TG = GG. 
 
 
Figure 8. Modes of genetic action with respect to the minor allele (G allele frequency is 30%). 
Observations are individuals (n=100). The risk of disease increases along the y-axis but units are 
arbitrary.  
There is also a fourth mode of action, where the highest risk is experienced by 
heterozygotes (TG). This scenario is considered to be rare and will not be discussed in 
this thesis. 
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A common misconception is to think that one mutation will have an effect on only 
one trait. This is rarely (and, arguably, never) the case. A genome is not a product of 
"intelligent design". It was grown by accidental rearrangements and natural selection, 
which reused and recycled genetic code fragments with one function to other 
fragments with slightly different functions. Due to such semi-stochastic design, all 
functions are interconnected; many genes cannot function without a proper function of 
other genes. Differently than in intelligent design, e.g., car manufacturing, knocking 
off one gene can have effects on numerous phenotypes, as compared to a single 
malfunctioning taillight. Similarly, a single phenotype, e.g., human height, can be 
affected by thousands of genetic variants, all contributing to the phenotypic variation. 
These scenarios together with their technical concepts - pleiotropy and polygenicity 
- are explained in Figure 9. 
 
Figure 9. Pleiotropy and polygenicity. How variation in human genome (SNP; single-nucleotide 
polymorphism) can affect variation in the phenotype. 
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5. Goals 
The goal of all three studies in this thesis was to increase our understanding of the 
biology of human gestation and parturition. This work was done with a hope that 
minor increments in knowledge would eventually lead to effective preterm birth 
prevention methods: that children would not die and their parents would not suffer, 
that in the adulthood they would be whole and healthy, that society could spend more 
resources elsewhere and that researchers could concentrate on the next big problem. 
 
Study I 
In Study I our goal was to find genetic factors and processes modulating the 
pregnancy length. In particular: to identify SNPs that are statistically associated with 
gestational age and to explore which genes could be implicated by discovered SNPs. 
 
Study II 
In Study II we designed a new method that could provide reliable evidence of 
causality for the factors known to be associated with gestational age. Our goal was to 
test this method with maternal height data. 
 
Study III 
In Study III our goal was to find a biological explanation for the causal relationship 
between maternal height and the child's gestational age. In particular: to formulate a 
plausible falsifiable hypothesis and to design a quasi-experiment that could refute it. 	  
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6. Data and Study Population 
6.1. Genomic studies (I and II) 
The dataset of Study I, and two additional datasets used in Study II are enriched in 
PTD cases and depleted from late preterm and early term pregnancies. Consequently, 
the phenotypic data (gestational age) follows a bimodal distribution (Figure 10) 
atypical to naturally occurring phenotype. 
 
Figure 10: Bimodal distribution of gestational age at birth in three genomic cohorts is due to 
strategic sample selection. 
The preterm birth oversampling was strategic. Since maximal statistical power in a 
case-control study is achieved with case-control ratio 50:50, a random sample from 
the population (with case-control ratio 5:95) was not optimal. All three genotype-
phenotype datasets were created by different research groups/institutions with a single 
goal in mind - to detect genetic variants affecting the risk for preterm birth. So the 
choice to enrich in cases was logical. 
The exclusion of  "mid-range" gestational age values (255-279 days in DNBC*; 
259-272 days in MoBa; 252-260 days in FIN) was also done for a reason. Having the 
inaccuracy of GA-dating methods in mind, all involved parties wanted to have the 
lowest rate of phenotypic misclassifications. As a general rule, with a constant sample 
size, the estimated effect size of a true genetic factor will be larger if cases and 
controls are defined from a continuous distribution using more extreme thresholds. At 
the same time, p-values for a true genetic factor will be lower. Since genotyping is a 
relatively costly data collection procedure, there is a need to optimize the sample 
selection strategy to gain maximal power with a given budget.

* The DNBC, MoBa and FIN cohorts are described in detail in the same subchapter, below.  
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6.1.1. MoBa data (Sudies I and II) 
In Study I, all genotyped individuals are part of the Norwegian Mother and Child 
Cohort Study (MoBa)78,79. In brief, MoBa is a nationwide prospective pregnancy 
cohort, including more than 108,000 pregnancies during the period of 1999-2009. 
Women were recruited by postal invitation in connection with the routine ultrasound 
examination offered to all pregnant women in Norway at around 17 gestational weeks. 
Over a period of two decades, participants were asked to fill eleven questionnaires 
focused on health, lifestyle, diet, and anthropometrics (e.g., maternal height used in 
Study II). Pregnancy and birth records were added via personal number from the 
Medical Birth Registry of Norway80 (e.g., gestational age used in Studies I and II, 
birth weight/length/head circumference used in Study II). Blood samples were 
collected from both parents during pregnancy and from mothers and children 
(umbilical cord) after birth. Biological material (DNA, RNA, whole blood, plasma 
and urine) was stored in a biobank. 
Professor Bo Jacobsson’s group did the first genotyping effort in the MoBa cohort 
in 2008, with a grant from the Research Council of Norway. It covered 2000 mothers 
and 1200 children, some of whom form the mother-child pairs (N pairs = 1017). The 
sample selection was done randomly in preterm (154-258 days) and term (273-286) 
strata of non-compromised singleton live-born pregnancies with spontaneous delivery. 
The case-control ratio was close to 50:50. Genotyping was done using Illumina's 
Human660W-quad_v1 DNA bead chips with more than 500,000 common genetic 
markers at Oslo University Hospital genotyping core facility.  
6.1.2. DNBC data (Study II) 
All genotyped individuals are participants enrolled by the Danish National Birth 
Cohort81. DNBC is a prospective nationwide cohort, in many aspects similar to MoBa. 
DNBC enrolled more than 100,000 pregnant women in the first trimester from 1996 
to 2003.  
The genotyped dataset contains approximately 1000 preterm and 1000 term 
singleton pregnancies. For each pregnancy, both mother and child are genotyped. The 
vast majority of children had parents and all four grandparents born in Denmark. 
There are no children born with recognized congenital or genetic abnormalities, and 
no mothers with declared medical conditions known to be associated with PTD. Also 
there are no pregnancies with major PTD-risk conditions: placenta previa, placental 
abruption, polyhydramnios, isoimmunization, placental insufficiency, preeclampsia/ 
eclampsia. All deliveries were spontaneous. 
Blood samples (buffy coat) were collected for mothers and children. Genotyping 
was done using Illumina's Human660W-Quad_v1_A bead chips at Johns Hopkins 
University Center for Inherited Disease Research (Baltimore, Maryland, USA). For 
Study II, the DNBC data was retrieved from the public database dbGap82. 
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6.1.3. FIN data (Study II) 
 
The Finnish case-control cohort (FIN) was assembled specifically for genetic studies 
of preterm birth. Whole blood samples were collected from ~900 mother/child pairs 
from the Helsinki University Hospitals between 2004 and 2014. Gestational age at 
birth was evaluated using the UL method (crown-rump length, first ultrasound 
screening, 10-13 weeks). Collaborating nurses manually collected relevant phenotypic 
data. Only spontaneous, singleton births were included. Mothers and their children 
were of Finnish descent. The pairs were excluded due to PTD-related pregnancy 
problems, maternal medical problems, and fetal congenital problems. The final 
sample contained 783 mother-child pairs. Genotyping was done at Washington 
University, Vanderbilt University genotyping center with the grant support from the 
March of Dimes Foundation and the Fifth Third Foundation to Professor Louis J. 
Muglia. Several genotyping platforms were used: Affymetrix Genome-Wide Human 
SNP Array 6.0, Illumina HumanOmni2.5-8v1_A, Illumina HumanOmniExpress 
Exome-8v1-2_A, Illumina InfiniumOmniExpressExome-8v1-3_A. The number of 
SNPs on each chip type was 0.9, 2.2, 0.9, and 0.9 million, respectively. Imputation 
was used to ensure that all samples have genotypes from all SNPs. After imputation 
and quality control, all samples had genotypes for 9 million SNPs.  
6.2. Epidemiological study (III) 
6.2.1. Swedish Medical Birth Register data 
All data in Study III comes from the Swedish Medical Birth Register. In Sweden, 
all births are compulsorily recorded in this register since 1973, regardless of mother's 
the birthplace and including even home deliveries. The register is managed by 
Sweden's National Board of Health and Welfare (Socialstyrelsen), which also stores 
and manages many other datasets linked by personal identity numbers. Researchers 
can apply to access the data but are never given personal identity numbers.  
The register contains more than 4 million pregnancies and an extensive list of 
variables describing maternal anthropometrics, social and behavioral characteristics, 
medical conditions, pregnancy complications and characteristics, delivery 
complications and characteristics, child's weight at birth, gestational age, and many 
more. 
Due to the missingness of some exclusion-filter indicators before the year 1990, 
only the pregnancies with births in year 1990 and onwards were included. 	  
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7. Study I: GWAS 
Literature-informed analysis of a genome-wide association study of gestational 
age in Norwegian women and children suggests involvement of inflammatory 
pathways 
7.1. Background 
7.1.1. GWAS principles 
The genome-wide association study (GWAS) is a powerful tool to investigate the 
genetic architecture of complex traits. A typical GWAS one-by-one compares up to a 
million positions on a genome between those who have a trait of interest and the 
control individuals. If the control group at a particular position of the genome on 
average tends to have a different nucleotide than a case group, then researchers can 
suspect that this polymorphic site is associated with the trait, and that genes in a close 
proximity might be involved in a molecular aetiology of it.  
The single-nucleotide polymorphisms (SNPs) that are used in genotyping are 
carefully pre-selected to represent a large fraction of inter-genome variability. The 
simplest form of analysis is done by comparing the frequencies of two alleles within 
each polymorphic position between the case and control groups of individuals. A 
statistical test is used to determine whether the difference in frequencies is improbable 
enough to be generated only by random sampling. The probability of such a 
difference to emerge only by chance, under the assumption that there is no real 
association, is represented by a p-value. The lower the probability - the smaller the p-
value and the lower the confidence in the assumption of no association. While directly 
arguing against the null hypothesis*, a low p-value indirectly argues for the alternative 
hypothesis.   
The great value of GWAS is not at predicting individual's risk for certain diseases 
but identifying, with a high level of confidence, the genes that are influencing it. How 
could the knowledge of genetic factors be used for preterm birth prevention? After all, 
we cannot modify our genomes yet. The answer is simple and comforting. Even 
though genome editing is off the table, pharmacological interventions can affect gene 
transcription, can target gene transcripts (mRNA) and their products - proteins. The 
comforting part is that no gene functions in a solitude. Their transcripts and proteins 
act and interact in biochemical pathways, each consisting of numerous other players. 
Thus, a single implicated genetic variant can offer a large and varied flock of targets. 
The more genetic risk factors we know, the better we can tell what role they are 
playing in biochemical pathways and the easier it is for us to find a safe way of 																																																								
* The null hypothesis is the default position, a claim that there is no association. In a classical 
significance testing approach (Ronald Fisher), we look for evidence against the null.  
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stimulating and dimming the players of those pathways to restore the equilibrium 
specific to term-delivering women. 
7.1.2. GWAS history 
GWAS has already identified many SNP that are associated with the risk for lung 
cancer83, celiac disease84, Crohn’s disease85, Type 186 and Type 287 diabetes, 
Alzheimer’s disease88, Parkinson’s disease89, and thousands more90. Its popularity 
rose with an advent of genotyping microchips in 2005 (Figure 11). 
 
 
Figure 11. Published scholarly work using GWAS. Data source - Scopus (accessed 2018 Sept). 
7.1.3. From SNPs to drugs 
After a GWAS discovers a significant genetic variant (SNP) but before clinical 
pharmacology can take a shot at developing the drug, a lot remains to be done. The 
SNP might not be causal, but only correlate with some unobserved (not genotyped) 
truly causal mutation. This mutation must be shown to have even stronger association 
with the phenotype. Mutation must be mapped to a gene. Experimental evidence must 
be collected; indicating that specific allele of the mutation affects the expression of 
that gene. The direction of this effect must be determined. Association between gene 
expression levels and the phenotype must be confirmed. Gene implicates biochemical 
pathway. Often, a gene can be part of many pathways, thus more GWAS discoveries 
are needed to point out the pathway that is affecting the phenotype. Members of this 
pathway become the targets of clinical pharmacology research. To this day, there is 
only a small number of GWAS discoveries that went through all the way and reached 
the shelves in a form of drugs.  
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7.1.4. Statistical power 
Statistical power calculations are often run before the experiment to determine how 
many study subjects would be needed to properly falsify the hypothesis. However, 
GWAS is a hypothesis-free experiment. In it, we do not know what exactly we are 
looking for. We do know that genetic effects are involved, but nothing more precise: 
neither SNP's effect size, nor its minor-allele frequency. Figure 12 shows dependency 
of statistical power (the probability that a true causal SNP will be discovered) on the 
study size and two parameters describing the causal SNP. If someone would tell us 
that we are looking for a SNP with MAF=0.2 which decreases gestational age by 3 
days per every copy of effect allele, then we would be certain that genotyping 2000 
individuals should be sufficient to identify this SNP. But there is no one to reveal to 
us such hidden information. So instead, we run power calculations after GWAS, to 
show what types of SNPs did have a fair chance of being detected, but were not. 
 
Figure 12. Power simulation for GWAS of gestational age. Statistical power depends on the study 
sample size (N), minor-allele frequency (MAF) of the SNP and its true effect size (Beta). The 
simulation assumed additive genetic mode of action, 1 million independent tests (i.e, genome-wide  
p-value threshold is 5e-8), normally distributed gestational age with mean=280 days and SD=9.7. 
Beta is interpreted as absolute difference in mean gestational age between genotypic groups AA vs 
AB, and AB vs BB. Power greater than 0.9 spans towards the upper right corner from every curve.   
7.1.5. The advent of large national datasets 
The new and very powerful genome-editing tools would be useless without the 
knowledge about how our genomes function. Thus, there is a recent trend in national 
strategies aiming to collect as much phenotypic and genotypic information as 
possible. Today, governmental funding agencies of many countries are convinced, 
that massively genotyping or sequencing their population is a good idea in order to 
N
500
1000
2000
104
105
Power
0.9
0.7
0.8
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tackle health issues (Table 2). Many GWAS studies will come soon as a result of 
well-funded efforts to genotype a significant fraction of populations. Similarly, an 
interest to participate in genome research is observed among private companies: 
23andMe (USA), AstraZeneca (USA), BGI (China). 
 
 Table 2. Countries leading in genotyping a large fraction of population. 
Country Cohort name 
Project size 
(individuals) 
Fraction of 
population 
Iceland DeCODE 172 000* 51% 
Finland FinGen 500 000 9.1% 
Norway MoBa79 300 000 5.7% 
Norway HUNT91 250 000 4.8% 
Estonia EGCUT92 52 000 3.9% 
UK UK Biobank93 500 000 0.76% 
USA Million Veteran Program94 690 000† 0.2% 
USA "All Of Us"  1 000 000‡ 0.3% 
Project size reflects the existing or projected number of individuals with genome-wide 
genotyping data. Unofficial data from personal communications. The numbers are 
approximate and the list is not extensive.   
7.1.6. Advantages of genomic studies 
The methods investigating genotype-phenotype associations have an advantage over 
methods exploring biomarker-phenotype associations. The "biomarker" here is a 
placeholder for tissue- and time-specific entities or phenomena, e.g., proteins, gene 
transcripts (mRNA), DNA methylation patterns. Such non-GWAS methods are 
especially problematic in preterm birth studies.  
Firstly, gene expression is widely varied across tissues. It is unclear which types of 
cells should be investigated when searching for biomarkers: leukocytes from blood, 
myocytes from myometrium, trophoblastic cells from placenta etc. This imposes an 
additional research hypothesis. A poor choice of study biomaterial will result in a 
whole budget wasted on non-significant results. But more importantly, the cell types 
that are most likely to hold a key to the secrets of human pregnancy are not accessible 
to analytical investigation due to potential risks to mother or the fetus. Biopsies of the 
human endometrium or fetal tissues would never even be considered by ethical review 
boards.  
Secondly, unlike genomic studies, gene-expression studies investigate biomarkers 
that are changing in time. The levels of certain gene transcripts might follow the time 
passed since conception. But similarly, these levels might mark the time remaining till 
parturition. Without a possibility to collect bio-samples at a certain time-point before 																																																								
* Might currently be much closer to 100%. 
† As of August 2018  
‡ The first version of dataset is expected in 2019 
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the delivery in all study subjects, any observed association between gene-expression 
levels and gestational age at birth will represent anything but the explanation for 
biology of preterm birth. Needless to say, such task of bio-sampling pregnancy 
exactly one week (for example) before delivery is not practically feasible. 
Thirdly, unlike genomic studies, gene-expression studies do not imply causality in 
the discovered associations. There is a possibility, that a certain confounder, e.g. a 
regulating protein is triggering both the parturition pathway and also up-regulating an 
unrelated pathway that includes the gene being analyzed. All three shortcomings are 
also unavoidable in epigenetic studies, investigating the methylation (silencing and 
activation of certain regions) of the human genome. 
The conclusion here is that GWAS studies do not fall victim to the aforementioned 
problems, because the genetic code is the same across all somatic tissues, is constant 
over time and, according to the central dogma of genetics, only causes things to 
happen and is not being caused. 
7.1.7. Previous attempts at finding PTD genes 
There were only two GWAS studies that investigated the timing of delivery before 
our Study I was published. None have identified SNPs that are robustly associated 
with PTD. 
In 2013, three years before our Study I, the GWAS results from DNBC cohort were 
published95. The study investigated 22 autosomal chromosomes (without chromosome 
X) and included 849 preterm births and 949 term births as controls. Only fetal 
genomes were used. The authors did not find genome-wide significant hits. They also 
chose not to publish the list of top SNPs. 
In 2015, one year before our Study I, the GWAS results from the Genomic and 
Proteomic Network (GPN) for Preterm Birth Research were published96. This study 
included subjects from the USA (only 68% of which were Caucasian) - both mothers 
and children. In the maternal group there were 935 cases and 946 controls, while the 
fetal group contained 916 cases and 935 controls. The spontaneous PTD was defined 
by gestational age at birth being less than 34 weeks; the control group was defined by 
birth between 39 and 42 weeks of gestation and with no history of PTD in any prior 
pregnancies. The researchers could not replicate their findings in a validation cohort.  
7.2. Summary of the study 
Since up to 30% of variation in human gestational age could be accounted for by 
heritability, we were motivated to identify some of the genetic factors using GWAS. 
We screened 500,000 genotyped variants across all chromosomes without making 
any prior assumptions about their function. This is called a "hypothesis-free" 
approach, as opposed to a "hypothesis-driven" approach, in which we would only test 
SNPs in candidate genes. Both maternal and fetal genomes were tested. Separate 
analyses were run with deliveries initiated by labor and those initiated by prelabor 
rupture of membranes (PROM). 
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The GWAS did not reveal genome-wide significant associations. However, we 
observed a robust significant enrichment in phenotype-relevant candidate-gene sets. 
We interpreted this as an indication, that our GWAS ranked variants in a phenotype-
relevant manner, and that increased sample size would confirm some of the “false 
negatives” to be “true positives”. We also noticed, that a high fraction of top 
implicated genes were previously reported in a context relevant to preterm birth. 
Based on a literature search, many of the top implicated genes form interacting 
networks and often belong to the infection-inflammation pathways, which are lately 
emerging as an important etiology element of human parturition. 
The value (application) of this study is twofold: 1) it provides a reasonably short 
list of polymorphisms that could be used as candidates in replicating studies with 
limited sample size: due to a low burden of multiple-tests small studies might still 
have enough statistical power to confirm our reported associations. 2) GWAS might 
benefit from our study design: inclusion of recessive and dominant genetic models 
was advantageous, because allelic interactions (dominance effects) implicated 
approximately 90% (more than expected by chance) of genes with biological 
relevance; similarly, 30% of genes (more than expected by chance) would have been 
overlooked if a minor-allele frequency filter (MAF > 0.1) were to be applied, and over 
50% would have been lost if a GWAS sample size were to be “increased” by mixing 
PROM-delivering mothers (N = 336) and mothers with labor-initiated deliveries (N = 
1407). 
7.3. Novelty 
Despite no robustly implicated genes in Study I, it is worth highlighting some novel 
aspects implemented in this study. We realised that the earlier study designs95,96 could 
be improved in numerous ways, by either avoiding some obvious shortcomings or 
designing new features. 
The first decision was to recognize that dichotomizing a continuous phenotype 
reduces its variance and, in most cases, should reduce statistical power of the study. 
This recognition was lacking in the previous studies. As a result, we chose to use 
continuous gestational age instead of its dichotomized form.  
The second novel aspect was acknowledging the existence of different etiologies of 
parturition. If delivery was initiated by PROM, then the resulting gestational age 
becomes less informative of genetic effects that affect the "risk" of labor. Similarly, if 
delivery was initiated by labor, the resulting gestational age is less informative of 
genetic effects that affect the risk of PROM. Without a clear distinction between these 
two endophenotypes the statistical power will suffer. For that reason we ran analyses 
separately in pregnancies that started with PROM and labor. 
The third novelty was eliminating prior assumptions about the genetic model. 
Typically, a GWAS study would assume an additive allelic effect, i.e., that the three 
possible genotypes will have an effect on the phenotype ordered in magnitude 
depending on the dosage of a risk allele: AA > AB > BB. While this is a good rule of 
thumb, there might be scenarios in which such assumption would result in reduced 
statistical power. In particular, dominance models where AA=AB>BB, or 
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AA>AB=BB. We repeated every GWAS two additional times corresponding to these 
two dominance models. 
The fourth methodological improvement was the use of adaptive permutations to 
adequately control the Type I error rate inflated due to the use of dominance models 
and continuous phenotype with a skewed distribution.  
7.4. Limitations 
Upon reflection, Study I has limitations. We did not attempt to replicate our 
findings in an independent cohort. No imputation was done (statistically inferring 
non-genotyped SNPs). Some arbitrariness still remains, e.g., the number of top SNPs 
used in enrichment. We also speculated that the results might not replicate in the 
cohorts from other countries, because many reported genes are infection-related, and 
infection rates and types are likely specific to different geographical areas. The 
decision not to use the MAF filter might disproportionately increase the number of 
erroneously genotyped SNPs. Case-oversampling and unnatural phenotypic 
distribution complicates comparability of the effect size with the results from other 
studies. The use of linear mixed models (LMM) would have allowed us to include 
more individuals who now were excluded due to excessive cryptic relatedness. 
Similarly, with LMM, the phenotypes from other pregnancies of the same mother 
could have been utilized. Since gestational age by its nature is a “time-to-event” 
phenotype, it would be most appropriate to use Cox model (proportional hazards 
regression, or survival analysis); this would also allow having PROM-initiated 
deliveries and labor-initiated deliveries in the same analysis.  
7.5. Methodological aspects 
7.5.1. Genomic-data cleaning: mistakes in data 
The most time-consuming stage of any genomic study is data cleaning, also called 
"quality control" (QC). The goal of this process is to minimize the error rate in the 
data received from the scanner. 
Genotyping is done on a massive automated scale but in micro dimensions. All 
downstream analyses are based on an implicit assumption that all genomic positions 
of all individuals were evaluated (genotyped) correctly. Needless to say, a lot of 
things could go wrong in the genotyping facility: DNA samples could have too low 
concentrations, or be contaminated with reagents or other DNA; some types of 
magnetic beads (probing a certain SNP) could fail to attach to the array, the tag 
sequence could fail to attach to the bead, or DNA-bead attachment could fail. On a 
massive automated scale, these problems always happen. 
There are various QC filters invented to detect and eliminate mistyped genotypes. 
Unfortunately, none* of them can tell exactly which genotype is wrong. The reader 																																																								
* Except QC filter using family data and Mendelian Errors. 
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could visualize a table with 10 individuals (rows) and 10 SNPs (columns); a genotype 
would be a single cell in such a table of 100 cells. Instead, a typical QC filter 
highlights the SNP, which has unlikely genotypes at many individual samples; and 
similarly the sample, which has unlikely genotypes at many SNPs. In other words, the 
QC detects the SNPs and samples that are not worthy of trust. There are numerous 
filters that indicate such poorly performing SNPs and samples (Table 3). 
 
Table 3. Genomic QC filters detect SNPs and samples that are not worthy of trust. 
SNPs samples Filter name Description 
+ + Missingness A large fraction of not called genotypes indicates low DNA quality or concentration, or failed SNP chemistry. 
+  Minor-allele frequency 
A too low frequency can lead to an unreliable genotype 
assignment during genotype calling (clustering step) 
 + Heterozygote frequency 
A too high or too low fraction of heterozygous 
genotypes indicates a DNA sample contamination 
+  Hardy-Weinberg equilibrium 
Genotype frequencies are discordant with frequencies 
that are theoretically expected from allele frequencies. 
+ + Mendelian  errors 
Detects impossible genotypic combinations between 
close family members. 
 + Sex chromosomes 
Mismatches between declared and genetically inferred 
sex indicate sample-identity problems. 
 + Identity by descent (IBD) 
Discordant relatedness in declared and genetically 
inferred pedigrees indicates sample-identity problems. 
The first two columns indicate whether the filter is designed to detect problems in indivduals 
(samples) or the features (SNPs). The list is not extensive. 
Troublingly, a lot of arbitrariness is involved in the QC. The same QC filters can 
give different results depending on how they are applied. In the worst-case scenario, 
the QC will result in an over-conservative elimination of trustworthy genotypes, thus 
reducing the economic efficiency and statistical power of the study. This could be 
illustrated in a simulated example (Figure 13), where 3 out of 20 genotyped samples 
had low DNA concentration (and thus - low genotype calling rate). Similarly, a low 
call rate was enforced on 2 out of 20 genotyped SNPs. In the simulated QC, a 10% 
missingness filter was applied, meaning that any SNP or any individual with a 
fraction of called (non-missing) genotypes lower than 90% will be considered as 
“bad” and not to be trusted in analyses. 
By design, the perfect QC would mark 3 samples and 2 SNPs as unworthy of trust, 
thus deleting only 94 genotypes (3×20 + 2×20 − 2×3). The best-performing method 
(7) in the simulated example deleted 130 genotypes, thus sacrificing 36 additional 
genotypes for no good reason (9% of total). The worst-performing method (1) deleted 
50% genotypes without evidence ((292-94)/400), while two standard methods (2 and 
3) deleted 25% and 43%, respectively. 
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Figure 13. Simulation "same QC - different results". The importance of the order in which SNP and 
sample filters are applied, also the effect of an iterative approach with a dynamic filter threshold 
(increasing stringency gradient). The final threshold for the missingness filter is 10%. Methods: (1) 
both filters applied simultaneously; (2) SNPs, then samples; (3) samples, then SNPs; (4) four cycles 
of method 2; (5) four cycles of method 3; (6) five cycles of method 2 with thresholds 50, 40, 30, 20, 
and 10%; (7) five cycles of method 3 with thresholds 50,40,30,20,10%. The dimension distortion 
parameter describes how much the cleaned dataset deviates from the raw dataset, with a value equal 
to “0” when the dimension ratio is kept similar to the original data. Asterisk (*) - for visual purposes 
SNPs and samples were reordered and clustered. 
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This example shows the importance of using an iterative approach with a dynamic 
filter threshold. In this example, only the most basic QC filter was used, but the 
principle applies to any two filters, one pruning SNPs and the other pruning samples.  
As a concluding remark, I would like to note that every step in a QC pipeline 
affects the outcome of the following steps. A careless ordering of the QC steps might 
lead to the poorly cleaned or overly pruned data. Since there are many types of filters, 
the final QC pipeline could quickly become very complex. A considerable amount of 
time in this project was spent on designing an optimal sequence of QC filters. To my 
knowledge, such thorough approach is rarely taken in the genomic data QC.  
7.5.2. Genomic-data cleaning: bias in data 
Besides not trusting the genotyping quality of certain samples and certain SNPs, there 
are more dangerous issues to consider. A different type of QC tries to avoid bias and 
inflated Type I error rate in the downstream analysis by not allowing some samples 
and some SNPs to enter the analysis stage.  
Cryptic relatedness. Individuals randomly selected from a small population will 
be to some extent related among each other. However, that would violate the main 
assumption in association analysis - observations must be independent. It is therefore 
important to prune the dataset by eliminating one individual from each pair of related 
individuals. We treated each pair as “related” if genetic similarity was equivalent to or 
greater than that between cousins (PI_HAT>0.125). The challenge then was to 
determine which individual from a pair to remove. The choice should not be a random 
one, but rather be a function of genotyping data quality for that individual, the 
membership in a mother-child pair (more valuable), and phenotype missingness.  
Population stratification. In GWA studies, whenever the phenotype has non-
homogenous worldwide prevalence or distribution, the possibility of geographical 
confounding must be taken into account. In the simplest case, the study population is 
“homogenized” by excluding individuals who are “ethnic outliers” based on many 
polymorphisms in their genomes (principal components analysis, PCA). This 
procedure is sensitive to inclusion of related individuals (e.g., mothers and children). 
The standard bypass of this problem would be to run PCA on unrelated individuals 
who are “founders”. However, such approach would be an oversight, as in our data it 
would mainly select mothers as analytical subjects for PCA, and then, if a mother is 
selected for exclusion, her child would automatically be also, since they share 50% of 
their genomes (and thus, at least 50% of “ethnicity”). The subtle problem with this 
approach lies in the fact that the fathers are not genotyped in our data. The child’s 
genome represents both maternal and paternal ethnicities, while the mother’s genome 
provides no clues about the father’s ethnicity. The procedure would only eliminate 
confounding risk in GWAS of maternal genomes, but would not fully eliminate 
possibility of confounding in GWAS of children. My solution to this problem was to 
identify ethnic outliers in mothers and children separately. 
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7.5.3. Genome-wide association analysis 
Permutation-based statistical significance testing is regarded as the gold standard97. 
Conventional asymptotic statistical tests are evaluated and validated by comparing 
their results to the ones generated using permutations. In Study I, the need for 
permutation-based association testing is illustrated by quantile-quantile (QQ) plot in 
Figure 14, where a clear inflation of Type I error is seen when a skewed phenotype 
and a recessive model are used. Since only the null hypothesis was designed to be 
valid for all the SNPs (due to random phenotype assignment), the transformed and 
ranked GWAS p-values were expected to fall on or very close to the black line. The 
"upward" deviation of observed p-values from their expected values is equivalent to 
Type I error, i.e., calling SNPs as being associated with the phenotype when, in fact, 
they are not. This is due to a violation of one assumption behind the linear regression. 
The inflation is mostly attributed to the skewed phenotype (setups B and D), but 
recessive model also adds to inflation when used together with the skewed phenotype 
(setup D). 
 
Figure 14. Inflation of Type I error rate in GWAS due to skewed phenotype and recessive genetic 
model. We ran 500 GWA analyses for each setup (A-D). Each time in A and B the phenotype was 
randomly drawn from normal distribution, while in C and D it was randomly sampled from naturally 
skewed distribution of gestational age. Recessive model is defined with respect to minor allele. 
Genetic data is from Study I. In each GWAS, p-values were log-transformed and ranked. After 500 
iterations, the distribution of -log10(Pval) at each rank position (e.g., for the top SNP) was 
summarized by certain percentiles (small numbers). The chosen percentile colours give visual aid in 
reading the quantile-quantile plot (median line, white) and its empirical confidence intervals (50%, 
75%, 90%, and 95%, from light blue to dark). Expected p-values were drawn from uniform 
distribution. The black line has an intercept 0 and beta 1.  
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How could this undesirable phenomenon happen in the first place? And how can 
permutation-based regression solve it? Let's examine a simplified example in Figure 
15, where the data consists of only 100 individuals. The SNP has a minor-allele 
frequency of 10%, thus the number of individuals in the minor-homozygote group is 
1. The remaining 99 individuals belong to a single combined genotypic group. In both 
experiments, the lone individual happens to have the most extreme (the lowest) 
phenotypic value from the whole cohort. Thus, the p-value describing statistical 
significance behind genotype-phenotype association is the same as the answer to the 
school-level mathematics problem: "what is the probability to draw an orange from a 
basket with 99 apples and 1 orange?". In both experiments, the empirically correct 
level of surprise* that we should have, when observing such data with the null 
hypothesis in mind, is equivalent to 1/100. But even more surprisingly, this is not the 
p-value that the linear regression gives us.  
 
Figure 15. The importance of permutation-based association testing. Observations (individuals) are 
coloured based on their genotype, recessive model with respect to the minor allele is used. Both 
depicted scenarios are equally psychologically surprising under the null hypothesis of no association. 
Since they both argue equally strongly against the null, their p-values should be the same, as is 
indicated by empirically estimated p-values from permutation-based testing. In this example, linear 
regression grossly inflates statistical significance. 
The reason for this is that linear regression has certain assumptions, which are 
violated in the first experiment. Namely, when the phenotype is not distributed 
normally, in a setting where the predictor has only several levels and a low number of 
observations in one (or some) of them, the model residuals will be heteroscedastic and 
not normally distributed. One solution to this is enforcing the phenotype to have a 
normal distribution (undesirable). The other solution is getting rid of linear regression 
and using permutation-based regression instead. 
 
																																																								
* The p-value is the probability to observe association as extreme as in experimental data, but under 
an assumption that association is not real and arose only due to chance. This probability summarizes 
our level of surprise in seeing unexpected patterns. The smaller the probability, the less we believe in 
the assumption of "pattern is due to random chance", and the stronger we believe in favour of an 
alternative explanation "pattern is due to causes". 
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Similarly to the thinking described in a school-level mathematics problem, 
permutation-based regression shuffles the phenotypic values randomly and measures 
the strength of association. Then it repeats this null-hypothesis procedure a very large 
number of times. Finally, the strength of association witnessed in the real (non-
shuffled) data is compared to the distribution of accumulated values from permuted 
data. The fraction of accumulated values that are equal to or exceeding the witnessed 
strength of association is the empirical p-value. It is the most intuitive, the least biased 
(in fact, not biased at all), and the most correct evaluation of statistical significance. 
However, it comes at a price of having to run hundreds of millions of tests per single 
SNP. 
 
Multiple-test problem is notable in Study I, as we tested a half million genetic 
markers in eighteen GWA analyses each:  
where subtypes are labor-initiated or PROM-initiated deliveries, and types of 
genomes are mothers and children. The exploratory nature of our study requires 
adequate correction for multiple testing. However, as many of the tests are not 
independent, a high correlation between tests (SNPs) and analyses should be taken 
into account before considering correction procedures. Since none of the GWAS 
revealed even remotely significant associations, we spared ourselves from estimating 
the total effective number of tests and used generated p-values only to rank the SNPs 
for the use in post-GWAS analyses. 
7.5.4. Gene-set enrichment analysis 
Objective phenotype-related candidate-gene sets. There is a very large number 
of gene-sets (lists of genes representing various biochemical pathways) ready to be 
used in enrichment analyses However, testing every available gene-set for enrichment 
would impose enormous burden of multiple-test correction and reduce statistical 
power. It is also impossible to avoid subjectivity when selecting only some of the 
available gene-sets to test against the GWAS top genes. Since we needed a small 
number of objectively relevant gene-sets covering various aspects of the phenotype, 
we developed a semantic PubMed abstract mining tool, which takes as an input a 
keyword and outputs a list of gene names that were found in the large body of 
abstracts containing that keyword. In this way we eliminated subjectivity, reduced the 
number of potential gene-sets and maximized their representativeness. 
 
 
 
 
 
(3 genetic models) × (2 phenotypic subtypes + 1 mixed) × (2 types of genomes) 
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7.6. Impact and echoes 
In 25 months of its online presence, Study I was cited four times by other scientific 
publications (a higher rate than the Impact Factor of PLoS One journal) and was 
viewed or downloaded by readers 2250 times. 
As it became clear that Study I is statistically underpowered to detect GA-
associated SNPs on its own, in 2017 we recycled the data in our new GWAS meta-
analysis (not included in this thesis) with 40,000 genomes from the company 
23andMe's research participants and two other birth cohorts from Denmark and 
Finland. This turned into an impactful publication in the New England Journal of 
Medicine98, with 27 citations during its 12 months of online presence*. In here, we 
also re-used the literature-based candidate gene-set enrichment method that we 
developed in Study I. For the first time maternal genomic loci were found to be 
robustly associated with gestational length or preterm birth. The roles of these six loci 
showed significant biological relevance due to their known involvement in uterine 
development, maternal nutrition, and vascular control. Since then, we have replicated 
the findings in our yet another, currently ongoing GWAS meta-analysis with more 
than 100,000 maternal genomes.  
As a side note, just recently, a successful GWAS on prolonged gestation (post-term 
birth) was published99, also a large GWAS meta-analysis using fetal genotypes100. 
 
																																																								
* This publication was prominently featured in Bill Gates' speech during Presidential Symposium at 
American Society of Human Genetics meeting in Orlando, USA (October 18th, 2017).  
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8. Study II: Mendelian Randomization 
Assessing the causal relationship of maternal height on birth size and  
gestational age at birth: a Mendelian randomization analysis 
8.1. Background 
Among many environmental factors reported by observational studies as being 
associated with gestational age, one stands out as exceptional. It is maternal height*. 
Firstly, maternal height is a strong predictor of gestational age. Secondly, one 
hypothesis could elegantly explain this correlation: maternal height is only a proxy for 
uterine size. Due to fetal growth and limited uterine space, the fetal movements 
gradually decrease in frequency from the peak at 32 weeks101. Sometime at early term, 
fetal size starts to discomfort the uterine wall. Possibly mediated by inflammation102, 
uterine distention then initiates the delivery. As a consequence, mothers with smaller 
uteri (and shorter stature) should, on average, deliver earlier. Hence, the causal link 
between uterine size and gestational age. Furthermore, there should be no causal link 
between uterine size and phenotypes like birth weight or birth length (adjusted for 
gestational age), since it is possible for the “gestational clock” to stop ticking, but not 
possible for the fetus to stop growing. 
The aforementioned "causality via uterine stretch" hypothesis, if proven true, could 
be of huge value. Not because we want to "recommend" the pregnant women to be 
taller, but because the causal relationships have a potency to generate new hypotheses 
and probe the causal pathway deeper, until we find a component that we can 
modulate, thus reducing the risk of preterm birth. 
The goal of any Mendelian randomization study is to imply causality between two 
variables (exposure and the outcome). It is important, because very often correlations 
are observed only due to confounding effects, i.e., there is no direct causal 
relationship between two variables. For example, the reported maternal height vs 
gestational age correlation could be confounded by maternal age or socio-economic 
status (nutrition). Only if we would be sure that the relationship is causal, we could 
start deconstructing and explaining the mechanisms leading from the risk factor to 
parturition. 
As a background to Study II, it is important to mention that human height is a 
highly heritable trait. Approximately 80% of phenotypic variation can be explained by 
heritability. A very large GWAS meta-analysis103 (with a total number of individuals 
exceeding 250,000) reported 697 independent height-affecting SNPs that explain a 
large fraction (20%) of variance in height. 
																																																								
* From the perspective of the fetus, the mother and her traits are equivalent to environmental factors. 
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It also might be of value to mention a general observation that gestation length in 
mammalian species (including humans) scales proportionally to body mass, 
suggesting that this trait is constrained by body size16. 
8.2. Summary of the study 
Study II is an example of how genotyping data collected for GWA study can be used 
for a completely different purpose - to gain insights about environmental factors. The 
environmental factor was maternal height at pregnancy and our goal was to test 
whether it has a causal effect on birth outcomes (gestational age, birth weight, birth 
length).  
We constructed a genetic score based on 697 SNPs known to be associated with 
adult height. In all three cohorts (MoBa, DNBC, FIN), this score explained the 
expected 20% of the variance in maternal height. We also developed a novel 
Mendelian randomization method, which utilizes the non-transmitted maternal alleles 
of these SNPs as a genetic instrument for maternal effect. This was done to avoid 
confounding due to genetic sharing between the mother and the infant. The crucial 
stage involved inferring parental transmission of the haplotypes, also known as 
genome phasing.  
Gestational age was significantly associated with the non-transmitted haplotype 
score, while birth weight and birth length were not. These results demonstrate that the 
observed association between maternal height and gestational length is very likely 
causal. One possible way to explain such causal connection could be that mothers of 
shorter stature have smaller intrauterine space that imposes fetal-growth restrictions 
earlier than larger uteri of tall mothers, thus the child is likely to be born earlier. 
8.3. Novelty 
The major challenge in Study II was imposed by a fact that both mother and fetus can 
affect gestational duration. In a setting where the phenotype is a human pregnancy 
outcome, the only ethical (i.e., non-experimental) way to explore causal relationships 
is by using the Mendelian randomization method. Its strength lays in the randomness 
of allelic transmission. But in our setting, it also becomes a weakness: maternal and 
fetal genomes are correlated. This violates the principal assumption in Mendelian 
randomization - that genetic instrument (height-associated maternal SNPs) affects the 
outcome (gestational age) only via the suspected causal phenotype (maternal height). 
However, it is possible that instrument-outcome association arises only due to fetal 
effects created by the fetal genome. 
The novelty of our study came from a shifted perspective in how we mentally 
model the pregnancy outcome. We either believe that gestational age is coupled with 
the maternal genome, or the fetal genome. Instead, our perspective was to imagine 
maternal and fetal genomes as one pseudo-triploid genome, one third of which is only 
owned by the mother. With this thinking, the non-transmitted haplotype Mendelian 
randomization method was born. Genetic instrument created from non-transmitted 
maternal alleles will only represent the direct causal pathway: if we observe an 
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association between such genetic instrument and gestational age - we have seen the 
evidence of causality between maternal height and the child's gestational age. 
8.4. Limitations 
There was a statistically significant correlation between height genetic scores derived 
from the transmitted and non-transmitted maternal haplotypes, which means that 
assortative mating must be in action. This would not be surprising, as the positive 
correlation between the statures of spouses is common in western populations104. 
However, we took precautions to avoid bias arising from the correlation between 
transmitted vs non-transmitted alleles in mother, and maternal vs paternal alleles in 
the child. 
Heterogeneity must also be mentioned: in some analyses, the results of the three 
cohorts did not agree perfectly (S7 Table, Study II). In fact, the main conclusion 
seems to be driven solely by DNBC cohort. This might be due to the differing cohort 
sizes and inclusion criteria, but also due to differing environmental backgrounds* and 
differing reliability of reported height. 
Biological pleiotropy could not be ruled out, where genetic instrument influences 
the birth outcomes through other mechanisms. For example, the SNPs associated with 
adult height can also influence fetal growth rate, and this might bias the UL-dated 
gestational age. Even though we took precautions, a complete exclusion of biological 
pleiotropy is generally not possible when a large number of genetic variants are used 
to construct the genetic instrument105.  
The UL-method used for GA-dating assumes that all fetuses have the same growth 
rate as the reference cohort used to generate the reference growth curves. Thus, 
gestational age of children with tall mothers could be overestimated. Ironically, the 
less accurate GA-dating method LMP would not suffer from such bias. 
 
 
 
 
 
 
 
																																																								
* In a very healthy population, the phenotypic variance will be explained less by environmental 
factors and more by genetic influences, in contrast to a less healthy population with a large variation 
in the levels of environmental exposures. 
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8.5. Methodological aspects 
8.5.1. Phenotypic data cleaning 
In Study II, the quality control of phenotypic data was done by the author. Maternal 
height data in the MoBa cohort was self-reported. Mothers received questionnaires by 
post and filled them in private. Later, the hand-filled questionnaires were read using 
optical character recognition system. We noticed a fraction of incredible maternal 
height and weight values. After closer inspection it was clear that these impossible 
values form distinct clusters (Figure 16) that are unlikely to be random mistakes.  
 
 
Figure 16. Systematic errors introduced by optical character recognition algorithm while reading 
hand-written numbers. Blue points indicate errors (impossible values); blue cloud on the center-right 
shows the density of correct observations; blue-shaded areas are expected positions of errors if they 
were to be systematic, e.g., due to certain types of digit loss. The number of observations is shown 
next to each cluster. Data from a self-reported maternal Questionnaire-1 in MoBa.   
Instead, we realized that due to irregularity of hand-written numbers, in certain cases 
optical character recognition algorithm tends to loose "1" as the first or the last digit in 
the three-digit height values. For example, an entered height "173" can become "73" 
or "17". Similarly, when maternal weight was hand-written as a three-digit number 
with a decimal point (e.g., "62.5" kg), the algorithm interpreted it as "625" kg. A less 
common error was entering height in feet units instead of centimeters. Without this 
discovery, we would have had to eliminate these samples from analyses. 
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8.5.2. The non-transmitted haplotype 
The key component in our analyses was to determine which maternal alleles of 
height-associated SNPs were not transferred to the fetus. This would not be possible if 
data would contain only mothers or only children. Ideally, family triad (mother, 
father, child) would be used, but none of the three cohorts had paternal genetic data. 
In the case of family dyad (mother and child), identifying a non-transmitted allele is 
very straightforward only for some SNPs: if either or both of the dyad members are 
homozygotes, the allele transmission can be unambiguously determined from their 
genotypes. However, when both the mother and her child are heterozygotes at a 
particular SNP, then inference of allele transmission is impossible without additional 
data and algorithmic solution (Figure 17). 
 
Figure 17. Haplotype inference (phasing) in family-duo genotyping data. Stage 1: 
phasing using only Mendelian logic. Stage 2: phasing using additional information 
about haplotypes in the population (determined using sequencing methods). 
Horizontal lines represent chromosomes, vertical lines represent SNPs. Alleles 
highlighted in red cannot be phased using only Mendelian logic. 
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For each of these twice-heterozygous SNPs, we constructed a long-range local 
haplotype and compared haplotype sharing to determine allelic transmission. In other 
words, the transmission was revealed by neighborhing SNPs that were not twice-
heterozygous. 
Unexpectedly, we also noticed that phasing software Shapeit2106 (used for 
imputation procedures) unintentionally arranges its output in a way revealing maternal 
non-transmitted alleles. We used this accidental feature in the sensitivity analysis (not 
published in the paper), which agreed well with the in-house built method. 
8.6. Impact and echoes 
During the 37 months of its online presence, Study II was cited 30 times by other 
scientific publications from high-IF (Impact Factor) journals: Nature Reviews 
Genetics (IF=40), Nature (IF=40), Science (37), Nature Genetics (28), New England 
Journal of Medicine (79), PLoS Medicine (11), PLoS Genetics (6), Human Molecular 
Genetics (6), PNAS (10), Epidemiology (5). We achieved twice as high citation rate 
than the mean of PLoS Medicine journal. Study II was viewed or downloaded by 
readers 14,500 times and received good resonance in genetic conferences. 
Importantly, one of the journals citing Study II was the Nature Reviews Genetics. In 
this review107 of genomic causal inference tools, our method was highlighted in it's 
own new category in the section "Extensions of Mendelian randomization". 
One Nature study from an independent research group was directly inspired by our 
novel non-transmitted haplotype score Mendelian randomization method108. Three 
other studies followed suit109-111, the second one recommending it as a sensitivity 
analysis. 
To our knowledge, nothing similar to our non-transmitted haplotype MR method 
has been applied before. The findings of Study II were replicated in a new larger 
study (currently a manuscript), where we demonstrate two orders of magnitude higher 
statistical significance than reported originally. A direct consequence of the findings 
in Study II was the Study III.  
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9. Study III: Uterine Distension 
Uterine distention as a factor in birth timing: retrospective nationwide cohort 
study in Sweden.  
9.1. Background 
Study III was inspired by findings in Study II where we found evidence that maternal 
height causally affects a child's gestational age at birth. In Study II we already had a 
hypothesis on how this could be happening biologically. It involved several 
assumptions* and the central premise of uterine distention imposed by fetal growth. 
However, this hypothesis had to be challenged further112. 
The history of epidemiology is rich in "natural experiments", reaching the times of 
John Snow in the mid nineteenth century113. The idea of how to construct a 
falsification challenge to our hypothesis came from realization, that there are natural 
experiments modeling uterine distention in humans.  
The most obvious natural experiment modeling two levels of uterine distention was 
twin and singleton pregnancies. At any time in pregnancy, twins should, on average, 
occupy more space than singletons. When near term, tension forces experienced by 
uterus carrying twins should be larger than in singleton pregnancies. If parturition is 
triggered by hypothetical stress signals coming from overstretched uterus (or the fetus 
experiencing restricted growth space), then twins should, on average, be born earlier 
than singletons. That is the first challenge to the hypothesis, and it passes the test: the 
mean GA in twin pregnancy is ~37 weeks114, in triplets and quadruplets it is ~34 and 
~31 weeks, respectively115. Together with the mean GA in singleton pregnancy (~40 
weeks), these numbers demonstrate a textbook pattern of negative association 
between the human litter size and gestational age at birth116. We observed this pattern 
in our data (Figure 18). In fact, the association between the litter size and pregnancy 
duration is also well documented in other animal species117,118. 
Besides the twin vs singleton comparison, there was one additional component that 
eventually led us to the method used in Study III. Our next step in exploring uterine 
stretch hypothesis was to investigate the strength of association between maternal 
height and gestational age in various strata of both variables (Figure 19). We 
speculated that this association should be the strongest when the mother is relatively 
short and the child is born relatively early. Evidence suggested that this is exactly the 
case. 
These ideas have led to the method used in the Study III, where we pushed the 
challenge to the hypothesis even further. 
 																																																								
* One assumption is that maternal height is correlated with uterine size and with tension forces 
experienced due to stretch imposed by uterine load. 
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Figure 18. Distribution of gestational age in twin and in singleton pregnancies. Data from the 
Swedish Medical Birth Register (1990-2013). Mean gestational age (GA) in twins and singletons is 
254 and 280 days, respectively. Only spontaneous deliveries with live-born children, GA evaluated 
using ultrasound method. 
Figure 19. Effect of maternal height on gestational age at various windows of each variable. Each 
cell represents a sub-population within a 10-cm-window in maternal height (columns) and 20-day-
window in gestational age (rows), the center point of each window is shown on the axes. Colour scale 
indicates the effect size (days/cm). The cells that are not significant after multiple-test correction 
(15×11 tests) are assigned beta = 0 (white). The number of individuals in each cell determines the 
power (empirical probability) to detect effect size larger or equal to the effect size in the reference 
cell (marked with red dot): cells with <80% power are marked with grey crosses. Data from Swedish 
Medical Birth Register (1991-2012). 
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9.2. Summary of the study 
We used anthropometric data from the Swedish Medical Birth Registry to non-
invasively test the hypothesis that gestation-imposed uterine stretch can trigger births 
in normal human pregnancies.  
The quasi-experiment tested a hypothesis-derived prediction about a specific visual 
interaction pattern that should be observed when child's gestational age at birth is 
plotted against maternal height during pregnancy in two strata of uterine load. This 
pattern can be quantitatively evaluated using statistical significance of the interaction 
term between uterine load and maternal height in linear regression. Two natural 
models of large and small uterine load were found: twin vs singleton and large vs 
small for gestational age fetuses (LGA and SGA, respectively). At any time of 
pregnancy, twins and LGA fetuses should impose a larger uterine load than singletons 
and SGA fetuses. In both models, the observed (data-derived) interaction pattern was 
qualitatively identical to the predicted one. 
9.3. Novelty 
To our knowledge, none of the epidemiological studies investigating association 
between maternal height and child's gestational age at birth have gone further in 
exploring the causal mechanism. The novelty of our work is the insight that "uterine 
stretch" hypothesis predicts a specific visual interaction pattern that can be easily 
tested with the data accessible to epidemiologists in almost any country. If 
falsification challenge112 to this prediction fails, it could be taken as evidence arguing 
for the hypothesis.  
Another novel aspect in Study III is a regard to the competing background risks that 
can cause birth thus setting the gestational age*. 
9.4. Limitations 
The strength of association between maternal height and the child's gestational age is 
dependent on the GA evaluation method, e.g., short and tall mothers have mean GA 
difference of 4.3 days when UL-based dating was used, but only 2.8 days when LMP-
based dating was used119. This difference might be due to the fact that maternal height 
and fetal growth rates are correlated (due to genetic pleiotropy). Since UL method 
uses normal fetal growth rate in its assumptions, gestational age in tall mothers can be 
overestimated, and in short mothers - underestimated.  
Fetal growth rate was estimated from birth weight and gestational age using 
reference longitudinal growth curves derived from healthy pregnancies with term 
deliveries. It is possible that such growth curves would be biased when assigning the 
birth weight Z-score (equivalent to growth rate) to preterm-born children.  
These complex correlations between three main variables in Study III might have 
unintended effects on the interaction model. 																																																								
* see "Bathtub model" in the section Methodological aspects, "Simulation" 
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Lastly, it is important to emphasize another hypothesis that could explain the 
observed interaction pattern. Instead of gestation-imposed uterine distention, it 
describes gestation-imposed metabolic constraints120. 
9.5. Methodological aspects 
9.5.1. Interaction model 
A particularly challenging task was to find the best way to detect and visualize the 
interaction pattern. Eventually, the simplest method* was chosen out of half a dozen 
less traditional ones. Some of them are presented in Figure 20. 
 
Figure 20. Three alternative approaches explored for data analysis and visualization. Panel A: 
only extreme observations are analysed, where "extreme" is defined by the distance from the 
center (median) in a bivariate plot. There are 50 radial groups and 500 observations in each. 
Observations are coloured based on mean gestational age of the group. Birth weight Z-score is 
adjusted for gestational age using Marsal et al. method 121, and then adjusted for maternal height. 
Panel B: Singleton pregnancies are matched to twin pregnancies based on gestational age at 
birth. After that, seven bins of maternal height are formed, each 5 cm in size. Mean gestational 
age and 90% confidence intervals are estimated using bootstrap method for all 14 resulting 
groups of pregnancies. [continued] 

* Study III, Figure 2. 
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Panel C: Five boxes represent strata of increasing maternal height. X-axis is LGA frequency, 
where LGA is defined as birth weight Z-score >1.5 (SD); Z-score is adjusted for gestational age 
using Marsal et al. method. Vertical dotted lines show the LGA frequency in each stratum. Y-axis 
is gestational age at birth. Blue lines are smoothed moving averages, where colour encodes 
window size (from light to dark): 1000, 2000, 3000, and 5000 observations. Data: Study III. 
9.5.2. Simulation 
The use of simulation models is not unusual in preterm birth research122-124. Although 
not included in the Study III publication, the simulation was the key element that 
convinced us to publish the findings. It allowed us to use the classical hypothesis-
testing framework - a cornerstone of the scientific method.   
Simulation 1 was the background risk alone. In pregnancy, the background risk 
symbolizes a natural gestational clock, for millions of years fine-tuned by evolution. It 
represents all unobserved genetic factors shaping the duration of normal human 
pregnancy, regardless of maternal height, uterine size and fetal growth rate. 
Simulation 2 was informally named "the bathtub model". In it, metaphorically 
speaking, the time at which water spills out of the bathtub (gestational age at birth) is 
determined only by the volume of the bathtub (uterine size) and flow rate of water 
(fetal growth rate). No other factors were in place. Variation in spill time is 
deterministically caused by variation in volumes and flows. 
Simulation 3 was a biological modification of the bathtub model. In it, an 
additional component was introduced - a background risk. The background risk 
competes with the bathtub model, and the one, which happens to trigger the birth first, 
determines gestational age. 
As seen in Figure 21, only simulation 3 (Panel C) showed an interaction pattern 
qualitatively identical to the one observed in real data (Study III, Fig 2). Importantly, 
this was the model that we believed to be of closest resemblance to nature. 
 
Figure 21. Simulation results. Panel A: birth is triggered only by a baseline risk (unknown 
environmental and genetic factors); Panel B: birth is triggered only by interaction (fetal size 
reaching the uterine size capacity); Panel C: birth is triggered by competing baseline and 
interaction risks. Pregnancies with slow fetal growth are depicted in blue circles and modelled 
by blue regression line with 95% confidence intervals; pregnancies with fast fetal growth are 
depicted in orange circles and modelled by orange regression line with 95% confidence 
intervals. Simulation used 10000 observations in each scenario. 
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9.6. Impact and echoes 
 
Study III was published in BMJ Open journal in October 2018, a month before the 
defence of this thesis. No data on citations, views or downloads is available at the 
time of writing. 
Working on the ideas behind Study III inspired our extended research group to use 
the insight about competing risk events that determine pregnancy length in other 
projects. We hope that this insight will be useful to other researchers. 
Study III indirectly implicated inflammation-related candidate genes for a currently 
ongoing genotype-phenotype association study. 
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10. Ethical Approvals 
Individuals used in Studies I-III are anonymous. The personal identification numbers 
that are used to combine various data sources are known only by the data managers, 
e.g., the Norwegian Institute of Public Health (for MoBa data) and Swedish National 
Board of Health and Welfare (for the Swedish Medical Birth Register data).  
In MoBa cohort, written consent was received from all study participants* during 
the years of enrolment. The consent covers the use of biological samples, 
questionnaire data and medical records for scientific research purposes. Study 
participants have the right to opt-out from the study at any time, in which case their 
data would be deleted and biological samples destroyed. The informed-consent form 
for data collection was approved by the Norwegian Data Inspectorate (ref No. 
01/4325) and by the Regional Committee for Medical Research Ethics (ref No. S-
97045 and S-95113). Our study was approved by the Regional Committee for Medical 
Research Ethics in South-Eastern Norway (S-06075) and the Norwegian Data 
Inspectorate (05/016784). The approvals also apply to the Figures 2, 10, and 16 of this 
thesis. 
In the DNBC cohort, the genomic and phenotypic data collection for medical 
research purposes of preterm birth was approved by the Research Ethics Committee 
of the Capital Region (Copenhagen) under the ID number H-A-2007-0017. The 
approval also applies to Figure 10 of this thesis. All adult participants gave written 
informed consent. 
In FIN cohort, the Ethics Committee of Oulu University Hospital and Ethics 
Committee of Helsinki University Central Hospital approved the data collection. 
Permission to use genetic data for preterm birth studies was given by Cincinnati 
Children’s Hospital Institutional Review Board (Nr: 2011-2047). The approvals also 
apply to Figure 10 of this thesis. All adult participants gave written informed consent. 
As is the case in most genomic studies, if researchers would discover a carrier of 
highly detrimental mutation, they would not be ethically (or legally) allowed to 
contact and inform this study subject. Such decision and action could only be made by 
the data manager and only with a special decision of regional ethical review board. 
The Swedish Medical Birth Register is a national population-wide dataset, thus 
the informed consent is not required. The collected data is considered a public 
property but released to researchers only with a permission of regional ethical review 
board and after data manager approves the research plan. Study III was approved by 
ethical review board of Western Health Care Region in Sweden (Nr: 968-14). The 
same approval also applies to Figures 1-5, and 18-20 of this thesis. Additional 
approval (Nr: 576-13) applies to Figures 6 and 7. 
 
																																																								
* For children, consent was given by their mothers. 
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11. Future Challenges 
It seems that currently we find ourselves in an episode of scientific progress, which 
Thomas Kuhn125 referred to as "normal science" (juxtaposing it to the revolutionary 
episode - "paradigm shift"). Today, the scientists work within the central paradigm by 
doing "puzzle-solving", i.e., the progress is defined less by ingenious ideas but more 
by mundane tasks of applying known methods to new datasets. Thus, the steady 
progress relies on large investments in genotyping, sequencing, biobanking, 
infrastructure, analytical tools and pipelines.  
The field of biomedicine is fertile with small and large enigmas, all ready to be 
deciphered from the four-letter alphabet code to a meaningful language of pathways 
and mechanisms. Every biological trait has thousands of causal genetic variants, and 
technological advancements of the current Renaissance of Genetic Era are likely to 
find most of them. From the current perspective it seems that genetic epidemiologists 
will have enough work for at least a couple more decades, performing an important 
but rather dull task - doing more of the same, only with larger datasets and more 
reliable methods. 
But there are real challenges in the future, and in this chapter I would like to focus 
on them.  
11.1. Sharing and harmonization 
In the context of genomics, statistical power is our ability to correctly detect causal 
genetic factors. The power of statistical investigation monotonically increases with the 
number of study subjects used in it.  If we want to find most of the risk-increasing 
mutations, we must be able to detect even those that impose a very small effect on the 
phenotype. Moreover, we should also be able to detect mutations with large effect but 
very rare in the population. More of correctly detected factors mean a clearer picture 
of biology behind the disease. And the more we know about its biology - the more 
molecular targets we can aim at with pharmacological missiles. 
As the number of genotyped or sequenced human genomes will continue to grow, 
we will be faced with a problem of who owns the data and how easy it is to access it. 
Imagine that 1000 research groups each have genotyped 1000 individuals and 
discovered the most obvious genetic culprits (the "low-hanging fruits"). They 
published 1000 articles, each about one disease and each unable to account for any 
significant fraction of the total genetic component. However, the same amount of data 
has a tremendous power for big discoveries, but only if these groups would 
collaborate or decide to make their data open. For example, if 1000 genomes gives 
you a 80% power to detect a common genetic variant with minor-allele frequency 
(MAF) of 50% and effect size odds ratio (OR) >1.7, then, without any decrease in 
statistical power, 1000×1000 genomes could enable you to detect a much wider range 
of genetic variants: with MAF reaching as low as 5% and effect size as small as 
OR=1.05 (or also MAF=1% and OR=1.1). This is a stunning improvement. 
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For such cooperation and data sharing to flourish there must be a legal support and 
political will. Ethical framework will be needed that clarifies whether my genome is 
my property, or whether it is a collective data. Currently, researchers and their 
institutes do not have good reasons to share data, since access to the data defines their 
advantage over other researchers without it. Correct incentives by grant foundations 
could fix this. 
The next question is how to harmonize the phenotype data. Each genotyping project 
would have to include much wider variety of phenotypic questions to make their data 
useful to other research groups. 
11.2. Unintended consequences 
The most reliable way to eliminate an illness from a population is to wait long enough 
until the natural selection drives the causal alleles to extinction. Naturally, the waiting 
time is too long for us to benefit, as evolutionary changes could take longer than a 
lifespan of a civilization. Currently, our best method of coping with illness is, in 
essence, curing only the symptoms of what is often a genetic problem; meanwhile the 
true genetic cause is never eliminated and propagates through generations. The reality 
is even grimmer: since the dawn of medicine, we have constantly tinkered with our 
survival probabilities, gradually becoming invisible to the natural selection. At the 
same time, random mutations are introduced at a steady pace of 50 de novos per 
person126, thus the number of health-impairing mutations accumulates in the gene 
pool, and their frequencies, absent the selective pressure, drifts randomly. 
Such interference with self-regulating evolutionary process has never happened in a 
history of Life before. And someday we might be facing the consequences. Our strive 
for health and happiness might come back to haunt us in unexpected ways: at future 
extreme environments, in unpredictable events and catastrophes, or population 
bottlenecks (e.g., colonization of Mars). With reduced medical supplies, power 
shortages, no medical service, we might find ourselves extremely vulnerable to 
diseases of genetic origin that we once though we had tamed. Very far in the future, 
our descendants riddled with autism, arthritis, asthma and atherosclerosis might look 
back at us as irresponsible innovators. Maybe, in a similar way as we look back at our 
ancestors, who thought that fossil fuels have no side effects.  
Is there anything that could be done? The answers balance on an edge of modern 
ethics. If some form of artificial allele-frequency adjustment was to be introduced into 
our species, we should be very cautious about mistakes carelessly done in the 
beginning of the 20th century and look for means that do not trample the human rights 
and dignity. The knowledge of genetic risk factors can be used to introduce selective 
incentives for risk-allele carriers, e.g., to choose adoption instead of biological 
parenting in exchange for generous subsidies. We can only hope that such incentives 
will be wise and compassionate, because without humane artificial selection we will 
be stuck with the second option - genome-editing technologies. These carry great risks 
of unintended biological consequences and are prone to becoming the next source of 
inequality (i.e., "best genes for best money"). 
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11.3. Publishing for people 
The phenomenon of academic piracy serves as a barometer for injustice in the field of 
scholarly publishing. The current copyright laws are especially detrimental for 
education and research and have led to civil disobedience acts, such as "Sci-Hub", a 
searchable online database of stolen scholarly journal articles created by a "pirate in 
hiding" - Alexandra Elbakyan127. Earlier, a similar altruistic effort to make scientific 
research open and free to public have claimed a life of a brilliant programmer and 
activist Aaron Swartz128. 
According to the 2011 data, only 17% of articles were available as open-access, 
most of them (12%) immediately but some (5%) within 6-12 months of publication129. 
More than a third of all journals still publish papers behind a strict paywall 
(subscription-only model). Less than half have adopted a hybrid model, where papers 
are immediately made free to read for a fee if the authors wish, but most studies are 
still kept behind a paywall. Injustice comes from a fact that in a great majority of 
cases, the public tax money pays for the scholarly work: experiments, analyses, 
writing, reviewing (public service), editing, and publishing. At the same time, to 
access the material, university libraries are required to meet expensive subscription 
fees, while those outside the paywall are charged $20 - $50 to read a single article. 
Needless to say, this is unfair. Anyone should be able to access published results 
without the need to pay for it. Such injustice disproportionately affects low-income 
countries, by obstructing education and research and propagating inequality. 
During the last weeks of writing this thesis, eleven European funding organizations 
(including the Research Council of Norway and the Swedish Research Council for 
Sustainable Development) announced an open-access initiative that requires grantees 
to make resulting papers free to download, read, translate or otherwise reuse the work 
under Creative Commons copyright license CC BY* immediately on publication. 
The plan does not oppose the article-processing charges but wants to cap them. It 
also wants funders and universities to pay, not the authors. This initiative was inspired 
by open-access policy of the Bill & Melinda Gates Foundation, which also demands 
immediate open-access publishing. A few other funding agencies also use similar 
policies: the Wellcome Trust (UK) and the National Institutes of Health (USA). 
In a near future, publicly funded researcher will not be published in Nature, 
Science, Cell, The Lancet and other hybrid journals, unless they change the reading 
and publishing subscriptions into a single fee. The big challenge will be to implement 
this plan without a drop in quality of peer-review work, without transferred costs 
disincentivizing the less-funded or independent scientists, and without pushing high-
quality and high-prestige journals to extinction. 
All three studies listed in this thesis were published in open-access journals. 	  
																																																								
* https://creativecommons.org/licenses/ 
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